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1. Introduction 
1.1 Epidemiological and clinical features of head and neck 
squamous cell carcinoma 
Accounting for about 4% of all carcinomas worldwide and 5% mortality of all 
malignancies, head and neck cancer represents the sixth most prevalent carcinoma in 
humans. Head and neck squamous cell carcinoma (HNSCC), which arises from the 
mucosal epithelia of upper aerodigestive tract, occupies more than 90% of all head and 
neck tumors (Bose et al., 2013; Rothenberg and Ellisen, 2012). Anatomically, HNSCC 
principally occurs in the oral cavity, larynx and pharynx (Figure 1-1). Different tumor 
subsites reveal distinct microscopic features and severity of tumor progression. 
Consequently, therapeutic schemes and clinical prognosis vary significantly among 
various localizations (Molinolo et al., 2009).   
 
Figure 1-1: Anatomical structure and subunits of the head and neck.  
Head and neck region consists of paranasal sinuses, nasal cavity, oral cavity, larynx and pharynx 
(consisting of the nasopharynx, oropharynx and hypopharynx). Image source: 
https://www.cancer.gov 
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The use of tobacco and excess consumption of alcohol are so far identified as main risk 
factors which synergistically account for HNSCC occurrence (Leemans et al., 2011). 
Added risk factor caused by betel quid chewing has been identified in south-east Asia 
and India area (Chen et al., 2008; Jeng et al., 2001; Wang et al., 2017). In a subgroup 
of HNSCC patients, high-risk human papillomavirus (HPV) infection accounts for 
development of the oropharyngeal squamous cell carcinoma (OPSCC) particularly, 
which is also considered as an independent prognostic factor (Marur et al., 2010; 
Syrjanen, 2005). Although certain inherited diseases (e.g. Fanconi anemia) reveal 
similarly genetic susceptibility to HNSCC, they have a minor role as risk factors (Alter et 
al., 2005; Rosenberg et al., 2005). In the western states, public health measures have 
been carried out to reduce the use of tobacco and consumption of alcohol, hence the 
incidence of HNSCC in specific sites has been decreasing during the past several 
years. However, the incidence rates of oropharyngeal cancers are increasing 
dramatically, which is related to a high-risk HPV infection. Currently, approximately 70% 
of OPSCC and 25% of all HNSCC are caused by HPV infections (Deschler et al., 2014; 
Kostareli et al., 2012; Lewis et al., 2015). 
 
Worldwide, over 550,000 new patients are diagnosed with HNSCC and 380,000 deaths 
annually. However, incidence rates of HNSCC show significant differences across the 
globe (Figure 1-2). In Europe, HNSCC accounts for 4% of the cancer incidence, there 
were approximately 250,000 cases and 63,500 deaths in 2012 (Gatta et al., 2015). 
Whereas, in India, HNSCC represents the most common malignance accounting for 40% 
of all cancers (Warnakulasuriya, 2009). In Germany, oral and pharyngeal malignances 
are the 5th most common cancer in the male population. The age standardized rate per 
100,000 inhabitants of HNSCC was 21.7 for male and 5.2 for female (Figure 1-2).   
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Figure 1-2: Incidence and mortality of HNSCC in the world and Western Europe. 
Incidence and mortality of HNSCC in Western Europe are age standardized and calculated per 
100,000 inhabitants. Tumors of the lip, oral cavity, nasopharynx, other pharynx and larynx were 
included. Data and image were derived from database of World Health Organization and (Ferlay 
et al., 2010). 
 
Unfortunately, less than 50% of newly diagnosed cases with HNSCC will survive for five 
years. The prognosis of patients with HNSCC is mainly dependent on the stage of the 
primary diagnosed tumor, which is estimated by physical examination, Imaging 
diagnosis, cytology of lymph nodes and pathological evaluation (Argiris et al., 2008). 
Recently, HPV status has been identified as a prognostic factor in oropharyngeal 
malignances, as well as the traditional tumor, node, metastasis (TNM) staging system. 
Until now approximately 100 subtypes of HPV have been recognized, but HPV type-16 
(HPV16) is identified as high-risk oncogenic subtype, which accounts for more than 90% 
of HPV-related HNSCC (de Villiers et al., 2004; Gillison et al., 2008). Clinically, 
Oncogenic HPV subtypes can be evaluated with viral DNA in-situ hybridization (ISH) 
and p16 immunohistochemistry (IHC) (Venuti and Paolini, 2012). Approximately 25% 
HNSCCs contain HPV genomic DNA, encoding the viral oncoprotein, E6 and E7, 
expression of which inactivate the tumor-suppressor gene p53 and retinoblastoma (Rb), 
respectively (Stransky et al., 2011). In the infected cells unrest of cell cycle regulation is 
triggered, which is deemed to be the initiation of HPV-induced carcinogenesis. In the 
past, our lab demonstrated that the viral load and the presence of viral RNA patterns, 
which was better suited than p16 expression by IHC, identified a subpopulation of 
HPV16-induced OPSCC patient with a better clinical outcome (Holzinger et al., 2013; 
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Holzinger et al., 2012).   
 
Generally, HPV-related OPSCCs have a more favorable prognosis as compared to the 
HPV-unrelated tumors. Underlying reasons may conclude two major mechanisms. First, 
host-intrinsic factors, since HPV-related OPSCCs are more prominent in younger and 
healthier patients with fewer complications. Second, tumor-intrinsic factors of different 
OPSCCs reveal distinct genetic pathway alterations yielding increased therapeutic 
sensitivity (Burtness et al., 2013; Swanson et al., 2016). The favorable clinical outcome 
associated with HPV-related OPSCC has caused the conception of therapy alteration 
for the low risk subgroup patients. Clinically, it is emphasized on protocol of 
de-escalation of standard treatment with more local resection, a lower dose of 
irradiation, or de-intensified chemotherapy for HPV-related OPSCCs. In several trials, 
traditional cytotoxic drugs are replaced with targeted therapy to evaluate whether 
alternative schemes could be applied effectively to patients with HPV-related OPSCC 
(Bose et al., 2013). 
  
The detailed treatment scheme of an individual HNSCC is principally determined in a 
multidisciplinary combination, which include surgical techniques, irradiation delivery, 
chemotherapy, and targeted therapy (Argiris et al., 2008). About 35% of patients suffer 
from early-stage tumor, and as a result they are treated with either surgery or radiation 
therapy and reveal the potential to be cured with rates of 70-90%. However, the 
majority of patients with locally advanced stage tumor require multimodality treatment 
with surgery, combined adjuvant radiotherapy with or without chemotherapy (Argiris et 
al., 2008; Suh et al., 2014). Despite considerable development in both surgical 
resection and irradiation techniques, up to half of locally advanced HNSCC evolve to 
locoregional or distant recurrence within the first two years post treatment. Salvage 
surgery, re-irradiation alone or combination with chemotherapy have been applied for 
patients with recurrent or metastatic HNSCC, with response rates of approximately 20% 
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and median overall survival of 10-12 months (Brockstein, 2011). Recently, 
immunotherapy approaches, especially immune checkpoint inhibitors, have obtained a 
large amount of excitement and prosperity on the second line treatment of recurrent 
and (or) metastatic HNSCC. The next step will be to enlarge the immune-based therapy 
benefit to the first line treatment and to combine conventional therapy for favorable 
clinical response in HNSCC (Gotwals et al., 2017; Szturz and Vermorken, 2017).      
1.2 Molecular mechanisms of HNSCC pathogenesis 
Although over 95% of head and neck cancers are squamous cell carcinomas, 
heterogeneity is a significant attribute of HNSCC. The heterogeneous feature not only 
complicates accurate prognostication and effective therapy, but also hampering the 
identification of pathogenic gene and signaling cascades (Leemans et al., 2011). 
However, preliminary studies show the existence of various molecular classifications of 
HNSCC, such as basal, mesenchymal, atypical and classical, which are depending on 
the biological properties of differentially expressed genes in each subtype. A great deal 
of genetic and molecular studies have revealed characteristic changes in 
cancer-related genes and signaling cascades in pathogenesis and progression of 
HNSCC, most of those at chromosomes 3p, 8p, 9p, 11q,13q and 18q (Bernstein et al., 
2013; Deshpande and Wong, 2008; Pai and Westra, 2009). Accumulation of genetic 
and epigenetic alterations in genes functioning in carcinogenic signaling pathways, can 
lead to the formation of malignant phenotypes, which consisting of limitless replicative 
potential, sufficiency growth signal, ability to evade apoptosis, invasion, metastasis, 
angiogenesis and immune escape (Ferris, 2015; Hanahan and Weinberg, 2011; Negrini 
et al., 2010; Whiteside, 2017).         
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Figure 1-3: Progression model of phenotypic and genetic alterations in HNSCC.  
Head and neck carcinogenesis is a multistep clinical and histological progression from normal 
mucosa through the squamous dysplasia to invasive malignancy, which is triggered by the 
accumulation of genetic alterations. Involved genomic instability and alterative signaling 
pathways are depicted. Adapted from (Argiris et al., 2008; Pai and Westra, 2009).         
 
1.2.1 Cellular proliferation and tumor suppressor genes 
The TP53 and retinoblastoma (Rb) pathways are mutated in nearly all of HNSCCs 
leading to unending replicative capacity and immortalization. Somatic mutations in 
TP53 are observed in approximately 60%-80% of cases with HNSCC (Poeta et al., 
2007). An elevated rate of TP53 mutations in HNSCC is related to alcohol consumption 
and smoking history (Brennan et al., 1995). In tumors with wild-type p53, the abrogation 
of p53 function may be caused by other mechanism including expression of HPV viral 
oncoprotein E6, overexpression or amplification of mouse double minute 2 homolog 
(MDM2) and deletion of cyclin-dependent kinase Inhibitor 2A (CDKN2A) and p14/ARF 
(Carroll et al., 1999; Denaro et al., 2011; Vogelstein et al., 2000). Together with p53, 
other family members, p63 and p73, have been demonstrated to exert significant 
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functions in carcinogenesis of HNSCC (Ratovitski et al., 2006; Rocco et al., 2006). In 
HNSCCs, pRb is targeted early through deactivation of CDKN2A, encoding the cell 
cycle modulators p16/INK4A and p14/Arf/INK4B. Inactivation of p16/INK4A has been 
demonstrated consistently to associate with clinical poor outcome (Reed et al., 1996; 
Smeets et al., 2009), Nevertheless, the correlation of p14/Arf/INK4B with HNSCC 
prognosis remains controversial (Dominguez et al., 2003; Sailasree et al., 2008). 
CDKN2A mutations were observed in 7-9% of cases by whole-exome sequencing, with 
copy number variants in a further 25% of tumors (Agrawal et al., 2011; Stransky et al., 
2011). In HPV-related HNSCC, HPV E7 protein can inactivate the Rb pathway and bind 
RB1, result in up-regulation of p16/INK4A, which is a cyclin dependent kinase inhibitor. 
This HPV-related activation of p16 has been considered clinically as a functional 
surrogate marker for evaluation of HPV status (Schache et al., 2011).       
 
1.2.2 Overexpression of EGFR in HNSCC  
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of 
transmembrane receptor tyrosine kinases. Overexpression of EGFR is claimed to be an 
early and common event in HNSCC (Grandis and Tweardy, 1993; Hama et al., 2009; 
Ozanne et al., 1986). Both gene mutations and amplification have been reported, 
however, amplification of EGFR is not indicated as a reason for high EGFR protein 
expression or related-poor clinical outcome in HNSCC (Grandis and Tweardy, 1993; 
Licitra et al., 2011). Generally, EGFR overexpression triggers the activation of kinase 
activity through spontaneous dimerization of receptors. Constitutive activity of EGFR is 
driven by autocrine signaling via the co-expression of EGFR and its ligand transforming 
growth factor-α (TGF-α), which is regularly found in HNSCC and associated with an 
unfavorable clinical outcome (Quon et al., 2001; Zhu et al., 2013). However, reports on 
correlations between EGFR overexpression and clinical prognosis reveal conflicting 
data. In general, about 60% of the reports show a correlation between EGFR 
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overexpression and unfavorable prognosis, whereas 40% of those studies a negative 
consequence (Leemans et al., 2011). This may be due to the heterogeneity of HNSCC. 
Distinct downstream signaling pathways are activated in various tumors, which is 
attributed to inconsistent function of EGFR and anti-EGFR therapy resistance. The 
signaling pathways stimulated by EGFR include phosphatidylinositol-3-kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR), Ras/Raf/mitogen activated 
protein kinase (MAPK), Janus kinase(JAK)/signal transducer and activator transcription 
(STAT) (Figure 1-4) (Choong and Cohen, 2006; Hynes and Lane, 2005; Yarden and 
Sliwkowski, 2001). Potentially, such complexity affects the EGFR function in tumor cells, 
therapeutic effects and the clinical outcome of patients. Furthermore, different subsites 
in HNSCC reveal various EGFR expression levels, for instance, tumors in the oral 
cavity and pharynx tend to possess elevated EGFR expression than carcinomas of the 
larynx. Targeted therapy of EGFR can be achieved by inhibition of extracellular ligand 
binding with specific monoclonal antibodies (mAbs) such as cetuximab (cetux), or by 
inhibition of the tyrosine kinase domain using a small molecule compound. So far, cetux 
serves as the only FDA-approved and European Medicines Agency-approved targeted 
therapy in HNSCC and is employed with no correlation with EGFR status. 
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Figure 1-4: Major signaling pathways involved in head and neck cancer.  
EGFR, PI3K, RAS and JAK-STAT pathways are presented as examples for the main signaling 
pathways contributing to the pathogenesis of head and neck cancer. Ligand binding to EGFR 
triggers receptor dimerization and activation of downstream signaling pathways such as RAS/ 
RAF/MEK/ERK, PI3K/AKT/mTOR, and JAK/STAT. PTEN is a negative modulator of the PI3K 
pathway. JAKs are activated by binding to cytokine receptors. PI3K and RAS signaling cascades 
are also triggered by activated JAKs.  
1.2.3 PI3K-AKT-mTOR pathway 
One of the major downstream targets of EGFR is the PI3K signaling pathway, which 
has been demonstrated as one of the most commonly activated pathways in human 
cancer. Genomic alterations including mutation, amplification and rearrangements in 
multiple components of the PI3K signaling route, lead to the dysregulation of cellular 
proliferation, differentiation, migration and survival (Cancer Genome Atlas, 2015). 
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Thereupon, those contribute to an uncontrolled growth, metastatic capacity and 
resistance to treatment. There are three classes of PI3Ks with each own specific 
substrates. The class I PI3Ks are activated by growth factor tyrosine kinase receptor 
such as EGFR, and the catalytic subunit phosphorylates phosphatidylinositol 
1,4-bisphosphate (PIP2) to form phosphatidylinositol 1,4,5-bisphosphate (PIP3). PIP3 
belongs to the inner leaflet of the plasma membrane and interact with the Pleckstrin 
Homology domain of AKT and phosphoinositide-dependent kinase 1 (PDK1), which 
results in phosphorylation of AKT proteins within their catalytic domains T-loop (Thr308 
in AKT1). Another specific site of phosphorylation by the mTOR complex (mTORC2), 
which belongs to one of distinct complexes of mTOR is at Ser473 in AKT1. Activation of 
the PI3K-AKT pathway can be achieved via various mechanisms including mutation or 
amplification of PI3K, amplification of AKT, activation of oncogenes such as RAS, or 
mutation of tumor suppressor protein Phosphatase and tensin homolog (PTEN) 
(Bauman et al., 2012). PTEN suppresses signal transduction through the PI3K 
signaling pathway by converting PIP3 to PIP2. Loss of PTEN expression can be found 
in approximately 30% of HNSCCs and serves as an independent unfavorable 
prognostic factor. Furthermore, activating mutations of oncogene PIK3CA can be 
observed in a small subpopulation (10%-20%) of HNSCC patients, particularly through 
the mechanisms of gene amplification and low-level copy number augment (Cancer 
Genome Atlas, 2015; Murugan et al., 2008; Qiu et al., 2006). Whole exome sequencing 
studies show an elevated incidence of PIK3CA mutations in HPV-related HNSCC, 
suggesting PIK3CA mutations may interact synergistically with HPV E6 and E7 proteins 
in the progress of invasive OPSCC. All in all, the PI3K-AKT-mTOR axis plays a 
significant role in the carcinogenesis of HNSCC, implying a potentially consequential 
clinical implication. Therapies targeting the PI3K and related signaling pathway have 
been assessed in various phases of clinical trials (Bossi and Alfieri, 2016; Horn et al., 
2015; Isaacsson Velho et al., 2015; Swick et al., 2017).  
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1.2.4 Ras-Raf-MEK-MAPK pathway 
The extracellular signal-regulated kinases (ERK) / mitogen-activated protein kinase 
(MAPK) pathway (also known as the Ras-Raf-MEK-MAPK pathway) consists of small 
GTPases of the RAS family (HRAS, KRAS, NRAS) and members of RAF, MEK and 
ERK kinase (ARAF, BRAF, CRAF, MEK1/2 and ERK1/2) families, which are key 
regulators in the communication from the cell surface to the nucleus and regulate the 
progression of various carcinomas. Members of the Ras oncogene family are some of 
the most commonly mutated genes in human malignance. Activating mutations of 
HRAS occur in 4-5% of HNSCC cases and the other Ras genes are infrequently 
mutated in HNSCC (Agrawal et al., 2011; Stransky et al., 2011). Particularly in oral 
cancer of areca quid chewing patients, the Ras-Raf-MAPK signaling pathway can be 
triggered sequentially owing to gain of function mutations in Ras genes. Several reports 
show the MEK-ERK cascade can be activated in radioresistant cells of HNSCC (Affolter 
et al., 2017; Drigotas et al., 2013). Observations suggest that targeting ERK-MAPK 
pathway may sensitize the treatment of irradiation to HNSCC.  
1.2.5 JAK-STAT pathway 
JAKs are part of a family of non-receptor tyrosine kinases that are triggered by cell 
surface cytokine receptors through transphosphorylation. STATs, which were 
phosphorylated by activated JAKs, dimerize and translocate to the nucleus where they 
can activate transcription of the target genes. Similarly, JAKs can be activated directly 
by receptor tyrosine kinases (RTKs) such as EGFR, triggering the RAS-MEK-MAPK 
and PI3K-AKT pathways(Aaronson and Horvath, 2002; Constantinescu et al., 2008; 
Nefedova and Gabrilovich, 2007). The JAK-STAT pathway, which plays a role in 
facilitating cell proliferation and growth, has been related to head and neck 
carcinogenesis(Lai et al., 2005; Lai and Johnson, 2010; Song and Grandis, 2000). 
STAT3 is overexpressed in both HNSCC cell lines and tumor tissue specimens, which 
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serves as an early event in patients with smoking-related HNSCC (Grandis et al., 1998; 
Grandis et al., 2000; Nagpal et al., 2002). In addition, activated STAT3 is attributed to 
trigger Ras and EGFR signaling cascades (Arredondo et al., 2006). Although STAT3 is 
the most significant STAT molecule in HNSCC, several studies suggest that active 
STAT5 also sustains tumor development and resistance to therapy-induced apoptosis 
in HNSCC (Koppikar et al., 2008; Xi et al., 2003).       
 
1.2.6 Additional cancer-related genes and pathways  
There are also some additional candidate genes and pathways involved in molecular 
mechanisms of HNSCC, such as the transforming growth factor-β (TGF-β) (Oshimori et 
al., 2015), vascular endothelial growth factor (VEGF) (Vassilakopoulou et al., 2015), 
matrix metalloproteinases (MMPs) (Rosenthal and Matrisian, 2006), Notch-p63 axis 
(Mountzios et al., 2014), hepatocyte growth factor (HGF)/ (Met proto-oncogene) 
(Hartmann et al., 2016) and Wnt signaling pathway (Shiah et al., 2016). Moreover, 
HNSCCs reveal a great range of somatic mutations in genes implicated in antigen 
presentation and immune evasion, like CD274, HLA-A, B2M, TGFBR2 and TRAF3 
(Hammerman et al., 2015). The alterations in these or other genes may play a 
remarkable function in immune surveillance of HNSCCs.       
 
1.3  Preclinical mouse model for tumor recurrence 
As mentioned previously, 5-year survival rate of patients with HNSCC remains at 
approximately 50% due to a high rate of local recurrences and distant metastasis. 
Therefore, it is urgent to find better biomarkers that predict the subpopulation of 
patients at high risk for tumor recurrence and treatment failure and to unravel new 
targets for a more efficient and less toxic therapy. Already about 50 years ago the term 
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of “field cancerization” was proposed to interpret the great tendency of tumor relapse 
and treatment failure in HNSCC (Slaughter et al., 1953). The tumor-adjacent mucosal 
epithelium contains genetic changes, which is term “field”. In retrospective studies, local 
recurrences and second primary tumor after surgical resection remain to appear in the 
surgical margins (Roesch-Ely et al., 2007; Schaaij-Visser et al., 2009; Tabor et al., 
2004). To better understand the cellular and molecular alterations between primary and 
local recurrent tumors, Behren et al (Behren et al., 2010) developed a reliable and 
reproducible orthotropic floor-of-mouth squamous cell carcinoma murine model. 
Recurrent mouse tumors were collected after surgical resection of primary tumors. 
Global gene expression analysis was applied on matched specimens of primary and 
recurrent tumors derived from this mouse model and unraveled 49 differentially 
expressed candidate genes implying a crucial role during tumor relapse. One candidate 
gene encoded for Smr1, the murine homolog of human submaxillary gland 
androgen-regulated protein 3A gene (SMR3A), which belong to a gene family encoding 
the opiorphin-related pentapeptides.             
 
Figure 1-5: Preclinical murine model for tumor relapse after surgery. 
Mice were injected with SCC-7 cells to generate primary tumors and after microsurgical removal 
of the primary tumors local recurrences developed a high frequency. Matched specimens of 
primary and recurrent tumors were analyzed by global gene expression proofing, which 
disclosed a list of differentially expressed genes, shown in the heat map. One of the candidate 
genes encoded Smr1, the mouse homolog of human SMR3A gene (Acuna Sanhueza et al., 
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2012).      
 
1.4  The opiorphin gene family 
1.4.1 The pathophysiological function of opiorphin genes 
In humans, there are three homologous genes of opiorphin, OPRPN (known as ProL1 
previously), SMR3A and SMR3B (Tong et al., 2008). The opiorphin that corresponds to 
the mature pentapeptide product of the OPRPN precursor protein acts as efficient as 
morphine in a rat model of pain (Rougeot et al., 2003). SMR3A and SMR3B are two 
closely interrelated genes, both of which are potentially post-translationally processed 
to the identical opiorphin homolog. Previous studies revealed that aberrant expression 
of all three members of the human opiorphin family genes plays a key role in the 
modulation of erectile physiology (Tong et al., 2008). Furthermore, OPRPN-derived 
opiorphin have been demonstrated to act as a potent inhibitor of two cell membrane 
bound enkephalin-inactivating peptidases, namely neutral endopeptidase (NEP, also 
known as CD10) and aminopeptidase N (APN, also known as CD13) (Wisner et al., 
2006). CD10 and CD13 are widely distributed among a wide range of tissues and 
organs, where they fulfill distinct roles, for example, act as ectoenzymes to deactivate 
neuropeptides and regulate other signaling pathway mediating cell migration, 
proliferation and survival (Chen et al., 2012; Maguer-Satta et al., 2011; Mizerska-Dudka 
and Kandefer-Szerszen, 2015). Dysregulated expression of both protein has been 
shown in distinct human carcinomas, such as pancreas，gastric, prostate, breast, lung, 
and oral carcinomas (Erhuma et al., 2007; Kawamura et al., 2007; Piattelli et al., 2006; 
Sorensen et al., 2013).  
 
1.4.2 Opiorphin genes in HNSCC 
Our previous data revealed variable protein expression patterns for both CD10 and 
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CD13 in a cohort of patients with OPSCC. In addition, we also found strong SMR3A 
protein expression in 36% of all primary OPSCC by IHC staining of tissue microarrays 
(TMAs), which served as an unfavorable risk factor for survival of patients with OPSCC 
(Koffler et al., 2013). Regulation of SMR3A expression was further addressed in 
HNSCC cell lines after fractionated IR in vitro. Interestingly, an enrichment of 
SMR3A-positive cells was observed in the fraction of vital tumor cells after fractionated 
IR. Furthermore, up-regulation of SMR3A expression after fractionated IR was 
dependent on estrogen receptor 2 (ESR2) signaling (Grunow et al., 2017).  
 
1.5  Aims of the study 
So far, our group has addressed the correlation of SMR3A expression and clinical 
prognosis in HNSCC and provided experimental evidence supporting a model in which 
SMR3A serves as a surrogate marker for ESR2-dependent signaling in radioresistant 
tumor cells. The following work was performed to investigate: 
(1) the co-expression of ESR2 and SMR3A in tumor specimens of OPSCC and 
correlation with clinical feature; 
(2) the expression and clinical relevance of OPRPN, one homologous gene of 
opiorphin, in pathogenesis and treatment failure after radiotherapy; 
(3) the expression and regulation of ESR2 in established HNSCC cell lines under 
conditions of fractionated IR or targeted therapy (cetuximab). 
(4) the impact of drugs targeting the EGFR-MEK-MAPK pathway (e.g. Cetuximab and 
MEK1/2 inhibitor) on tumor cell survival and clonal expansion as well as 
expression of ESR2 and programmed death ligand 1 (PD-L1). 
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2. Materials     
2.1 Equipment and consumables 
Table 2-1: Equipment and consumables 
Equipment and consumables Providers 
Autoclave  Ibs Technomara GmbH 
Biochrom Anthos 2010 Microplate Reader Biochrom GmbH 
Black/White Camera XM10 Olympus GmbH 
Blotting System Mini Trans-Blot Cell Bio-Rad Laboratories, Inc 
Brightfield Camera SC30 Olympus GmbH 
Casy Cell Counter Schärfe System GmbH 
Cell Culture Inserts (Transparent PET 
Membrane, 0,4µm Pore Size) 
Falcon Technologies BD 
Cell Culture Plates (10cm-dishes, 96well-, 
48well-, 24well-, 12well-, 6well-plates, 25cm2-, 
75cm2-flasks) 
SIGMA-Aldrich, Inc. 
Cell Lifter Costar Corning Incorporated 
Centrifuge 5417R Eppendorf AG 
Centrifuge Tube (15ml, 50ml) SIGMA-Aldrich, Inc. 
Coverslips (12mmØ) Menzel-Gläser GmbH 
Coverslips (24x36 mm, 24x50mm) Menzel-Gläser GmbH 
Cryo Tube Vials (1,8ml) Thermo Fisher Scientific Inc. 
DAB substrate Dako GmbH 
DAKO PAP Pen Dako GmbH 
dd H2O Milli-Q Millipore, Merck KGaA 
Disposable Weighing Pans C. Roth GmbH 
DMEM SIGMA-Aldrich, Inc. 
Eppendorf Research Pipettes Eppendorf AG 
Erlenmeyer Flasks Brand GmbH 
Extra-thick Blot Paper Bio-Rad Laboratories, Inc 
Fetal Bovine Serum (FBS) SIGMA-Aldrich, Inc. 
Filtertips (10µl-1000µl) nerbePlus GmbH 
Fluorescence Microscope BX-50F Olympus GmbH 
Fluorescence Microscope BZ-9000 Keyence, Germany 
Forceps 37SA, 5SA VOMM GmbH 
Forceps, fine Fine Science Tools GmbH 
Freezer (-20°C) Liebherr Comfort Liebherr Group 
Freezer (-80°C) HERAfreeze Heraeus 
Freezing container SIGMA-Aldrich, Inc. 
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Fridge (4°C) Liebherr Premium Liebherr Group 
Funnel C. Roth GmbH 
GFL 1083 Shaking Waterbath 
GFL Gesellschaft für Labortechnik 
mbH 
Glas Beakers Fisher Scientific GmbH 
Glas Bottles Schott AG 
Glas Containers for Histology Schott AG 
Glas Pipettes (2ml, 5ml, 10ml, 20ml) Hirschmann Laborgeräte GmbH 
Graduated Cylinder, Glas Brand GmbH 
Graduated Cylinder, Plastic VITLAB GmbH 
Heating Block BiothermBT-11 Cryologic Pty. Ltd. 
Heraeus HERAsafe Safety Cabinet Kendro Laboratory Products 
Horizontal Gel Electrophoresis Chamber 
(Rotiphorese Chamber) 
C. Roth GmbH 
Ice-Machine AF20 Scotsman Ice Systems 
ImageQuant LAS500 GE Healthcare Europe GmbH 
Immobilon-P Transfer Membrane Millipore, Merck KGaA 
Incubator Unimax 1010 Heidolph Instruments GmbH 
L-Glutamine SIGMA-Aldrich, Inc. 
MicroAmp Fast Optical 96-well Reaction Plate Applied Biosystems, Life Technologies 
MicroAmp Optical Adhesive Film Applied Biosystems, Life Technologies 
MicroPlate 96-well  Greiner Bio-One GmbH 
Microscope Axiovert 25 Carl Zeiss AG 
Microscope BX-50F Olympus GmbH 
Microscope IX51 Olympus GmbH 
Microwave Robert Bosch GmbH 
MR200 Magnetic Stirrer Heidolph Instruments GmbH 
Nanodrop Spectrophotometer, ND-1000 PEQLAB Biotechnologie GMBH 
neoLab-Rocking Shaker neoLab GmbH 
Neubauer Chamber Brand GmbH 
Nuclease-free Reaction Caps, Safe Lock Eppendorf AG 
Parafilm "M" Brand GmbH 
pH-Meter 761 Calimatic 
Knick Elektronische Messgeräte 
GmbH  
Pipetman Classic Gilson Inc. 
Pipettetips (RFL-300-C, RFL-222-C, 
RFL-1000-C) 
Axygen Scientific 
Plastic Beakers Brand GmbH 
Plastic Containers for Histology Schott AG 
Plastic Pipettes Costar Stripette (5ml, 10ml, 
25ml) 
Corning Incorporated 
Power Supply Power Pac 300/300 Bio-Rad Laboratories, Inc 
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Precision Scales Sartorius AG 
Precision Scales Microbalance XS205 Mettler Toledo Intl. Inc 
Pump Cell Culture neoLab GmbH 
Reaction Tubes (1,5 ml, 2 ml) Eppendorf AG 
Rotilabo Magnetic Stirrer C. Roth GmbH 
RotoShake Genie Scientific Industries, Inc. 
Ruler Rotring GmbH 
SDS-PAGE System Mini-PROTEAN Tetra 
Handcast Systems (10well, 1,0-1,5mm) 
Bio-Rad Laboratories, Inc 
Shaker Polymax 1040 Heidolph Instruments GmbH 
Spectrafuge Mini Centrifuge Labnet International Inc. 
Spring Scissors, fine Fine Science Tools GmbH 
Staining Chamber/Humid Chamber C. Roth GmbH 
Steam-Cooker Multi-Gourmet Braun GmbH 
Super RX (18x24 cm) Fujifilm Europe GmbH 
SuperFrost Microscope Slides Menzel-Gläser GmbH 
TBC-Syringe (1ml) mediware, Servoprax GmbH 
Thermomixer Eppendorf AG 
Trypsin SIGMA-Aldrich, Inc. 
Vortex Reax 2000 Heidolph, GER 
Wet blotting transfer systerm Bio-Rad Laboratories, Inc 
Whatman Syringe Filters (0,2µm) GE Healthcare Europe GmbH 
XRAD320 Precision X-Ray Inc. 
2.2 Chemicals 
Table 2-2: Chemicals 
Chemicals Provider 
Acetic Acid Merck KGaA 
Acrylamide/Bisacrylamide C. Roth GmbH 
Agarose SeaKem GTG AppliChem GmbH 
Albumin from Bovine Serum (BSA) SIGMA-Aldrich, Inc. 
Ammonium Persulfate (APS) SIGMA-Aldrich, Inc. 
beta-Mercaptoethanol AppliChem GmbH 
Boric Acid SIGMA-Aldrich, Inc. 
Bromphenol Blue AppliChem GmbH 
Calcium Chloride (CaCl2) Merck KGaA 
Crystal Violet Merck KGaA 
Dimethyformamide AppliChem GmbH 
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Dimethylsufoxide (DMSO) SIGMA-Aldrich, Inc. 
Disodium Phosphate (Na2HPO4) C. Roth GmbH 
Dithiothreitol (DTT) Merck KGaA 
Ethanol p.a. SIGMA-Aldrich, Inc. 
Ethanol, denatured 99,7% SIGMA-Aldrich, Inc. 
Ethanolamine Merck KGaA 
Ethylenediaminetetraacetic Acid (EDTA) AppliChem GmbH 
Eukitt O. Kindler GmbH 
Glycerol C. Roth GmbH 
Glycine GERBU Biotechnik GmbH 
Haemalaun C. Roth GmbH 
Hoechst H33342 Biomol, Germany 
Hydrochloric acid (HCl) SIGMA-Aldrich, Inc. 
Hydrogen peroxide (H2O2) AppliChem GmbH 
Isopropanol SIGMA-Aldrich, Inc. 
Magnesium Chloride Hexahydrate (MgCl2 x 6H20) Merck KGaA 
Manganese (II) Chloride Dihydrate (MnCl2 x 2H20) Merck KGaA 
Methanol SIGMA-Aldrich, Inc. 
Milk Powder C. Roth GmbH 
Mowiol 4-88 C. Roth GmbH 
N,N,N’,N’,Tetramethyl-ethylenediamine (TEMED) C. Roth GmbH 
Natrium Chloride (NaCl) SIGMA-Aldrich, Inc. 
Non-fat Milk powder C. Roth GmbH 
Nonidet P-40 Fluka Chemie AG 
Paraformaldehyde (PFA) C. Roth GmbH 
Potassium Chloride (KCl) C. Roth GmbH 
Potassium Dihydrogen Phosphate (KH2PO4) C. Roth GmbH 
Sodium Citrate C. Roth GmbH 
Sodium Deoxycholate Merck KGaA 
Sodium Dodecylsulfate (SDS) Pellets C. Roth GmbH 
Sodium Hydroxide (NaOH) Merck KGaA 
Sodium Tetraborate SIGMA-Aldrich, Inc. 
Tris/Base (Trizma Base) SIGMA-Aldrich, Inc. 
Tris/HCl C. Roth GmbH 
Triton X-100 AppliChem GmbH 
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Trypan Blue SIGMA-Aldrich, Inc. 
Tween 20 GERBU Biotechnik GmbH 
Xylencyanol Merck KGaA 
Xylene SIGMA-Aldrich, Inc. 
Xylol VWR.Germany 
 
2.3 Molecular biological reagents 
Table 2-3: Molecular biological reagents 
Reagents COMPANY 
4-Hydroxytamoxifen SIGMA-Aldrich, Inc. 
cetuximab Merck KGaA 
DAB Kit Vector Laboratories 
Fulvestrant SIGMA-Aldrich, Inc. 
ImPRESS anti-goat Vector Laboratories 
MEK1/2 Inhibitor PD0325901 SIGMA-Aldrich, Inc. 
Pierce BCA Protein Assay Thermo Fisher Scientific Inc. 
Senescence-β-Gal staining Kit Cell signaling Technology, Germany 
TSA Biotin-System Perkin Elmer 
Vectastain Elite-ABC-Peroxidase Vector Laboratories 
Western Lighting Plus-ECL Perkin Elmer 
2.4 Antibodies 
Table 2-4: Primary antibodies 
 Primary antibody Application and 
dilution 
Species Company and product 
NO. 
anti-beta-Actin WB (1:25000) mouse Abcam, ab49900 
Anti-Estrogen 
receptor 
IF (1:100), WB 
(1:1000) 
IHC (1:900) 
rabbit Abcam, 133467 
Anti-ProL1 IF (1:200),  mouse Abcam, ab169504 
Anti-ProL1 IF (1:200), IHC 
(1:300) 
Rabbit Abcam, ab204562 
Anti-SMR3A IF (1:100) Rabbit Abcam, ab97942 
Anti-pERK1/2 IF (1:250), WB 
(1:1000) 
Rabbit Cell signaling 9101 
Anti-ERK1/2 WB (1:1000) Rabbit Cell signaling 4695 
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Anti-pAKT(Ser473) WB (1:2000) Rabbit Cell signaling 4060 
Anti-Histone H2A.X WB (1:1000) Rabbit Cell signaling 9718 
Anti-PD-L1 WB (1:1000) Rabbit Cell signaling 13684 
 
Table 2-5: Secondary Antibodies 
Secondary antibody Application and dilution Label Company  
Goat anti-rabbit IHC (1:200) biotinylated  Vector Laboratories 
Goat anti-mouse WB (1:10000) HRP Santa Cruz 
Goat anti-rabbit WB (1:10000) HRP Santa Cruz 
Goat anti-rabbit IF (1:200) Alexa488 Sigma-Aldrich 
Goat anti-mouse IF (1:200) Cy3 Sigma-Aldrich 
Goad anti-rabbit     IF (1:200) Cy3 Sigma-Aldrich 
2.5 Buffers and solutions 
Table 2-6: Buffers and solutions 
4% PFA 500ml 
200µl 
20g 
1xPBS 
NaOH 
Paraformaldehyde 
Borate Buffer 0,1M pH 8,4 25mM 
75mM 
100mM 
Sodium Tetraborate 
NaCl 
Boric Acid 
Crystal violet staining solution 500mg 
25ml 
75ml 
Crystal violet 
Methanol 
ddH2O 
Equilibration Buffer 20mM 
500mM 
Tris/HCl pH 7,4 
NaCl 
Mowiol 6g 
2,4g 
6ml 
12ml 
Glycerol 
Mowiol 4-88 
H2O 
0,2M Tris pH 8,5 
PBST 
 
0.05% 
1x                    
Tween-20 
PBS 
PBS pH 7,4  
(10x) 
20Mm 
27mM 
100mM 
1,37M 
KH2PO4 
KCl 
Na2HPO4 
NaCl 
Pre-Load Buffer 1M 
5mM 
5mM 
NaCl 
MgCl2 
MNCl2 
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5mM CaCl2 
RIPA Buffer 50mM 
150mM 
0,1% 
0,5% 
1% 
Tris/HCl pH 7,4 
NaCl 
SDS 
Sodium Deoxycholate 
Nonidet P-40 
SDS Running Buffer  
(10x) 
250mM 
2,5M 
1% 
Tris Base 
Glycine pH 8,3 
SDS 
Sodium Citrate Buffer  
(10x) 
100mM 
0,5% 
Sodium Citrate 
Tween 20 
TBS pH 7,4 (10x) 500mM 
1,5M 
Tris HCl ph 7,4 
NaCl 
T-Buffer 0,2% 
1% 
Tween 20 
BSA 
in 1xTBS 
TNT-Blocking Buffer (TNB) 1g 
200ml 
Blocking Reagent (TSA-Kit) 
1xTNT-Buffer 
Transfer Buffer 25mM 
0,15% 
25% (v/v) 
Glycine 
Ethanolamine 
Methanol  
Tris HCl – NaCl – Tween Buffer (TNT) 
(10x) 
1M 
1,5M 
0,5% 
Tris-HCl pH 7,4 
NaCl 
Tween 20 
Tris-Boric Acid-EDTA Buffer (TBE) 
(10x) 
20mM 
890mM 
890mM 
EDTA 
Tris Base 
Boric Acid 
X-Buffer 0,5% Triton X-100 
in 1xPBS 
2.6 Cell lines 
Table 2-7: Cell lines 
NAME Source Type, Characteristics Supplier 
FaDu Human, pharynx SCC, adherent ATCC 
Cal27 Human, tongue SCC, adherent ATCC 
Detroit562 Human, pharynx SCC, adherent CLS GmbH 
SCC4 Human, tongue SCC, adherent ATCC 
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SCC9 Human, tongue SCC, adherent ATCC 
SCC25 Human, tongue SCC, adherent ATCC 
 
2.7 Softwares 
Table 2-8: Softwares 
NAME COMPANY 
ADAP Biochrom GmbH 
Adobe Acrobat Reader 9.0 Adobe San Jose 
Adobe Photoshop CS5.1 Adobe San Jose 
Cell Sens Dimension 1.5 Olympus 
Clono Counter (Java based program)  
Endnote X7 Thomson Reuters (Scientific) Inc. 
Hamamatsu NanoZoomer (NDP Viewer) Hamamatsu Photonics 
IBM SPSS Statistics 20 IBM Corporation 
Image J (public domain, 
Java-basedimage processing program) 
W. Rasband, National Institutes 
ofHealth, Maryland, USA 
Microsoft Office 2016 Microsoft Corporation 
Nikon NIS-Elements 3.20.02 Nikon 
Nikon NIS-Elements Viewer 3.20.02 Nikon 
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3. Methods   
3.1 Cell culture 
3.1.1 Cultivation of cell lines and treatment 
Human HNSCC cell lines FaDu, Cal27, SCC4, SCC9 and SCC25 were purchased from 
ATCC (https://www.lgcstandards-atcc.org), Detroit562 from CLS (Cell Lines Service, 
GmbH, Germany http://clsgmbh.de/). Cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, 
Germany), 2Mm L-glutamine and 50μg/ml penicillin-streptomycin in a humidified and 
sterile conditions with 6% CO2 at 37℃. Mycoplasm tests were done routinely by PCR 
analysis using the PromoKine Mycoplasam PCR test kit. When culture reaching 80-90% 
confluency, the cells were passaged by adding 1ml 0.2% Trypsin in PBS/EDTA for 5 
minutes at 37℃. After detaching of cells trypsin reaction was terminated by adding 
DMEM containing FBS. Trypsinized cells were transferred to a Falcon tube and 
centrifuged at 1200 rpm for 3 minutes. The cell pellet was resuspended in the 
appropriate amount of DMEM and calculated in a counting chamber. The viability of 
cells was detected with trypan blue. According to individual experiment, cells were 
seeded in new culture flasks or on culture plates or dishes. For cryopreservation, the 
cells were trypsinized, counted with the number of 1x106 and resuspended in 1.5 ml 
freezing medium (10% DMSO in FBS-supplemented DMEM). For long-term reserve 
cryotubes were stored in liquid nitrogen. 
The cells were treated with several substances in the experiments. Details and 
concentrations were summarized as Table 3-1. 
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Table 3-1: Substances used for cell treatment.       
Substance Final concentrations Treatment 
Time  
Medium 
4-Hydroxytamoxifen 1μM Every 
24hours 
FBS free 
medium 
Fulvestrant 10nM for IF and WB, 30nM 
for CFA 
Every 
48hours 
normal 
medium 
Cetuximab 5,10μg/ml for WB, 2.5, 
5μg/ml for CFA 
Every 
48hours 
normal 
medium 
PD-0325901 0.1,1μM for WB, 0.1,0.3,1 
μM for CFA 
Every 
24hours 
normal 
medium 
3.1.2 Colony forming Assay 
To investigate the clonal expansion of HNSCC cells upon fractionated irradiation, 100, 
300 and 1000 cells were seeded per well in 6-well plates and irradiated on four 
consecutive days with a daily dose of 2 gray (Gy) using X-RAD 320 (Precision X-Ray, 
North Branford, CT USA) or kept untreated as controls. Half of the cells were 
administrated daily with 4-Hydroxytamoxifen (TAM, Sigma-Adrich, Germany), MEK1/2 
inhibitor PD0325901 (Sigma-Adrich, Germany) or every second day with Fulvestrant 
(Sigma-Adrich, Germany) at the indicated concentrations. To assess the sensitivities of 
tumor cells upon cetuximab or PD-0325901, 1000 and 3000 cells were seeded per well 
in 6-well plates. Half of the cells were treated daily with PD0325901 or every second 
day with cetuximab at the indicated concentrations. After 10-14 days in culture, clones 
were coloured with crystal violet and total amount of colonies was quantified as 
described in (Niyazi et al., 2007). The survival fraction was calculated using a freely 
available software Clono-counter according to (Franken et al., 2006).  
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Figure 3-1: Schematic protocol of the colony forming Assay 
Cells were seeded in six-well plates and treated with substances or IR as indicated time. After 
culture cells for 10-14 days, colonies were assessed by microscope. Staining with crystal violet 
was performed depending on the size of colonies. Number of colonies was counted by a freely 
available software Clono-counter.  
3.1.3 Immunofluorescence (IF) 
Cells were seeded on sterile coverslips in a 12-well plate and fixed with 4% 
paraformaldehyde for 15 mins at room temperature. After being wash with 
phosphate-buffered saline (PBS) three times. The cells were permeabilized with 0.5% 
Triton X-100 buffer in PBS for 30 mins, and after being wash again three times with 
PBS, blocked with 1% bovine serum albumin (BSA)/0.2% Tween 20 in 1x PBS for 30 
mins at room temperature. The primary antibody diluted in T-buffer with indicated 
concentrations was incubated with cells for 1 hour at room temperature or overnight at 
4℃. Following washing with PBS three times, the secondary antibody plus H33342 
diluted in T buffer was added for 30 mins at room temperature in the dark. Finally, cells 
were again washed with PBS for 3 times and embedded on glass slides with Mowiol. 
 34 
 
The glass slides were kept in the dark at 4℃ for at least 12 hours before taking 
pictures. 
 
3.1.4 Senescence-associated β-galactosidase (SA-β-gal) staining   
Cells were seeded on 6 cm dishes and treated with PD-901 as an indicated protocol. 
Cells were fixed in fixation buffer (provided in kit) and SA-β-gal staining was performed 
using a kit (Cell Signaling Technology, Germany) following with the manufacturer’s 
protocols strictly. Pictures were taken by Keyence microscopy and blue SA-β-gal 
positive cells ratios were quantified by ImageJ software.         
 
3.2 Protein biochemistry methods 
3.2.1 Protein extraction and determination of protein concentration 
Cells were seeded on a 10cm culture dish and harvested in cold 1x PBS after indicated 
treatment. Pelleted cells were resuspended in ice-cold RIPA buffer with freshly added 
protease inhibitor and phosphatase inhibitor cocktail (1:100). The samples were 
incubated for 15mins on ice and centrifuged at 4℃  for 10mins at 13,000 rpm 
(Centrifuge 5403, Eppendorf) to separate protein lysate from cell debris. The 
supernatant was collected and transferred to a new 1.5ml tube. An aliquot of 4μl was 
taken to determine the protein concentration.  
 
Protein concentration of RIPA lysates was measured utilizing BCA protein assay kit 
(Fisher Scientific Inc), which is a detergent-compatible formulation based on 
colorimetric reaction of bicinchoninic acid (BCA) with reduced Cu+2 to Cu+1 for the 
quantitation of total protein at 562nm. This method can be used for quantitation of 
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protein concentration since the reaction is linear in a certain range. RIPA lysates were 
diluted 1:10 in ddH2O and pipetted in triplicates into a 96-well plate. 200μl of BCA 
mixture reagent (reagent A : reagent B = 50:1) was transferred to each well. Parallelly, a 
dilution series of Albumin (BSA) standards ranging from 0 to 2000μg/ml was prepared 
according to manufacturer’s protocol and added to the plate as a standard curve. The 
reaction plate with slight shaking was incubated for 30mins at 37℃. The colorimetric 
value of each well was measured at 600nm with microplate reader (Biochrom Anthos 
Microplate Reader). 
3.2.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The sodiumdodecylsufate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed for protein separation. Firstly, the separation gel (10-15% 
acrylamide/bisacrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 0.1% 
TEMED) was prepared, then the stacking gel (4% acrylamide/bisacrylamide, 125mM 
Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0.1% TEMED) was added. The concentration 
of the separation gel was dependent on the target proteins. Equal amounts of protein 
sample (20μg) were mixed with 4 x Laemmli buffer and incubated at 95℃ for 5min, 
loaded onto the gel after cooling. A pre-stained protein marker (Fisher Scientific Inc) 
was loaded in one well in parallel. The gel electrophoresis was performed at 25-35Ma 
in 1x SDS running buffer. 
 
3.2.3 Western bolt 
Proteins separated by SDS-PAGE were transferred onto a polyvinylidene difluoride 
(PVDF)- membrane by wet blotting system from Bio-rad. The PVDF membrane was 
activated for 30seconds in methanol, washed for 2 mins in ddH2O and then incubated in 
1 x transfer buffer for 5mins. The blotting sandwich was prepared in following order: 
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anode plate, sponge, filter paper, PVDF-membrane, PAGE gel, filter paper, sponge, 
cathode plate. The sandwich was installed in a blotting chamber with ice for preventing 
overheating. The transfer was performed at 100V for 1h in 1x transfer buffer. After 
transfer, the membrane was blocked in 5% milk or 5% BSA in PBS/0.5% Tween (PBST) 
for 1h at room temperature on a shaker. The membrane was incubated with the diluted 
primary antibody with a indicated concentration () overnight at 4℃. Before and after 
incubated with the secondary antibody-HRP in blocking buffer for 1 h, the membrane 
was washed three times for 10mins in PBST on a shaker. The membrane was 
incubated for 1min with the enhanced chemiluminescence (ECL) solution. The signal 
was measured by ImageQuant LAS500 system with the appropriate time.         
            
Figure 3-2: Schematic diagram of wet electro-transfer technique.  
(modified from creative-diagnostics.com). 
 
3.3 Immunohistochemistry(IHC) with TSA  
Immunohistochemistry(IHC) is a standard method for the test of specific proteins on 
tissue sections with antibodies. The tissue sections on slides were deparaffinized in 
xylene for 10mins and then rehydrated in a decreasing concentration of ethanol series 
(100%, 100%,90%, 70%) for 3mins each. Endogenous peroxidase was blocked with 
3%H2O2 and 70% ethanol for 10min and heat-mediated antigen retrieval was 
performed in 10mM citrate buffer (pH6.0) for 30mins in a steam cooker. Then cooled 
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down for room temperature and washed shortly in ddH2O for 1min, in 1x PBS for 5min. 
During the time the tissue sections were encircled with a hydrophobic PAP pen. The 
slides were washed for five minutes in 1x TNT buffer before blocked for 30 minutes in 
TNB buffer in a humid chamber to prevent from drying off. Then the tumor tissues were 
incubated with the primary antibody diluted in 1x TNB buffer for overnight at 4℃ in a 
humid chamber. After removal of primary antibody the slides were washed 3 times with 
1x TNT buffer for 5 mins. Afterwards, they were incubated for 30 minutes with 
secondary antibody (diluted 1:200 in TNB buffer) in a humid chamber at room 
temperature. Next, three times washing were repeated. For signal amplification the 
slides were incubated in a humid chamber with streptavidin-HRP (diluted 1:100 in TNB) 
for 30 minutes at room temperature, washed three times in 1 x TNT buffer and 
incubated with biotin-labelled tyramide (diluted 1:200 in amplification diluent from 
PerkinElmer TSA kit) 10 minutes exactly at room temperature. The slides were washed 
repeatedly and incubated with streptavidin-HRP to enhance the signal for additional 30 
minutes again. Another washing in 1 x TNT was repeated. Next, the signal was 
developed using the DAB detection kit following the manufacturer’s manual and applied 
until a change in color was visible. Finally, the slides were washed with ddH2O briefly 
and counterstained using haematoxylin solution, washed for 10 minutes under running 
tap water subsequently. The tissue sections were dehydrated with increasing 
concentrations of ethanol series (70%, 96%, 100%, 100%) and xylene. The slides were 
embedded using Eukitt and observed using light microscopy.  
 
3.4 Tissue microarray (TMA)  
3.4.1 TMA production 
A tissue microarray (TMA) is a slide with circular tissue sections that cover samples 
from up to 200 patients. TMAs are created by punching cylindrical samples of tumor 
 38 
 
tissue and arranging these parallel to each other in paraffin. These paraffin blocks were 
cut with a microtome into 2-µm-thick sections. Paraffin-embedded tissue samples were 
provided by the tissue bank of the National Center for Tumor Disease (NCT) in 
collaboration with Dr.Flechtenmacher (Institute of Pathology, University Hospital 
Heidelberg) after approval by the local institutional review board (ethic vote 206/2005). 
For all patients, clinic-pathological and follow-up data were available from the 
Department of Otolaryngology, Head and Neck Surgery at the University Hospital 
Heidelberg.  
 
The retrospective study cohort included patients with OPSCC who were treated at the 
University Hospital Heidelberg between 1990 and 2008. The tumor samples include 
primary tumors as well as recurrence, metastasis and secondary carcinomas. For 
oropharyngeal cohort three TMAs (TMA 18, 19 and 20) were combined. Overall, they 
include 176 patients represented by 586 samples of primary tumors, recurrence, 
metastasis and secondary carcinomas and an additional 29 samples of healthy 
mucosa.  
3.4.2 TMA scoring  
TMAs were scanned utilizing the Nanozoomer HT Scan system (Hamamatsu Photonics, 
Japan) following accomplishment of IHC as clarified in 3.3. At least three experienced 
raters scored scanned TMAs slides by using NDP Viewer software. The 
semi-quantitative analysis was performed based on two independent categories: first, 
the relative number of stained tumor cells (score A ranging from 1 to 4: score 1 = no 
positive cells, score 2 = less than 33 %, score 3 = between 34 and 66 %, and score 4 = 
more than 66 % positive cells), and second, the staining intensity (score B ranging from 
1 to 4: score1 = no staining, score 2 = weak staining, score 3 = moderate staining, and 
score 4 = strong staining). Only primary tumors were included for the data analysis. 
Subsequently, the median score A and B were multiplied resulting in the final 
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expression score ranging from 1 to 16, which represented informative values for tumor 
specimens of patients. Accordingly, patients were arranged in different groups with 
various staining patterns. 
 
3.4.3 Statistical analysis 
Statistical analysis was performed by using IBM SPSS22 Software. Person and 
Spearman’s correlation analysis between score A and B were done before they were 
multiplied. The scores were correlated to patient’s data and clinical pathological factors. 
Differences of clinical pathological parameters between the groups were determined by 
χ2 test (chi squared test) or Fisher’s exact test.  
 
Disease-specific survival (DSS) was calculated as the time from the date of primary 
tumor diagnosis to the date of OPSCC-related death within the follow-up interval 
(events). Survival time of patients who were alive or were dead due to 
OPSCC-unrelated causes were censored. Progression-free survival (PFS) was 
calculated from the date of primary tumor diagnosis to the date of the first local 
recurrence, lymph node or distant metastasis, second primary carcinoma or date of 
OPSCC-related death within the follow-up period (events), or to the date of 
OPSCC-unrelated death or without progression (censored). The method of Kaplan–
Meier was used to estimate survival distributions and differences between groups were 
determined by log-rank tests. To adjust for possible con-founders, multivariate cox 
proportional hazard models were utilized.  
 
All experiments were performed in triplicate or duplicate independently. A 
representative figure is depicted for western blot. Statistical analysis of data was 
performed with Excel2016, IBM SPSS 22 and Graphpad Online QuickCalcs. Error bars 
represent standard error of mean (SEM). Student’s t test was used for comparisons 
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between groups. A p-value of 0.05 and below was considered as statistically significant 
(marked by*，** or *** as p-value <0.05, <0.005, <0.0005, respectively).  
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4. Results 
4.1 Co-expression of ESR2 and SMR3A in HNSCC and 
correlation with clinical features (Published) 
Our previous data provided an experimental evidence that a subpopulation of 
radiotherapy resistant malignant cells reveal co-expression of estrogen receptor 2 
(ESR2) and SMR3A after fractionated irradiation (IR) (Grunow et al., 2017). To 
investigate the clinical relevance of our vitro results, we evaluated ESR2 expression by 
IHC staining on TMAs containing tumor specimens of OPSCC patients, which were 
treated with either definitive or post-surgical radiotherapy with or without adjuvant 
chemotherapy. Evaluable staining specimens were obtained from 109 OPSCC patients 
(Figure 4-1A). Positive staining for ESR2 (ESR2pos) in tumor cells was detected in 65.1% 
of tumors and a high staining pattern correlated significantly with an elevated SMR3A 
immunoreactivity score as compared to specimens with undetectable ESR2 staining 
(Figure 4-1B). Subsequently, ESR2 expression pattern and clinic-pathological features 
were compared, it was not observed any statistically significant correlation between 
ESR2neg and ESR2pos subgroups except for age, T status and smoking. ESR2pos 
staining pattern was related significantly to older age, smaller tumor size and never or 
former smoking (Table 4-1). Next, Kaplan-Meier analysis and log rank testing were 
performed to reveal an unfavorable clinical outcome in ESR2neg as compared to 
ESR2pos tumors (Figure 4-1C-D). Nevertheless, patients with ESR2pos tumors had a 
significantly worse PFS and DSS in the presence of SMR3Ahigh expression, similar to 
the ESR2neg subgroup, whereas the pattern of ERSposSMR3Alow displayed the most 
favorable clinical prognosis (Figure 4-1C-D). Multivariable analysis by Cox proportional 
hazard regression models was performed to confirm that a subgroup of 
ERS2posSMR3Alow had a favorable PFS and DSS as compared to either 
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ESR2posSMR3Ahigh or all other staining patterns (Supplements). 
 
Figure 4-1: SMR3A and ESR2 expression in HNSCC patients.  
(A) Representative pictures of immunohistochemical staining (brown signal) of serial tumor 
sections with anti-ESR2 (left row) or anti-SMR3A antibodies (right row). Haematoxyline 
counterstaining (blue staining) demonstrates the tissue architecture. Scale bars = 500 µM. (B) 
Boxblot depicts the SMR3A immunoreactivity score as mean value and 5th/95th percentile for 
individual tumors with low, moderate or high ESR2 staining pattern(p=0.044). (C-D) 
Kaplan-Meier graphs show differences in DSS and PFS between subgroups without detectable 
ESR2 staining (ESR2neg, blue line) and ESR2-positive tumors with low (green line) or high 
SMR3A expression (red line). Published in (Grunow et al., 2017). 
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Table 4-1: Correlation of ESR2 expression with histopathological and clinical 
characteristics.  
RT, radiotherapy, RCT, radiochemotherapy, 1 viral DNA-negative or DNA-positive but 
transcript-negative; 2 viral DNA- and transcript-positive according to Holzinger et al 
(Holzinger et al., 2012); 3 Chi-square test. (pubished in (Grunow et al., 2017)) 
 
 
 
         ESR2neg ESR2pos         
Features Category N % N % p value3 
Age [years] < 57.5 25 65.8 30 42.3 0.019 
 ≥ 57.5 13 34.2 41 57.7  
Gender Male 33 86.8 50 71.4 0.055 
 Female 5 13.2 21 29.6  
T status T1-T2 10 26.3 33 46.5 0.040 
 T3-T4 28 73.7 38 53.5  
N status N0 4 10.5 8 11.3 0.906 
 N+ 34 89.5 63 88.7  
M status M0 35 92.1 66 95.7 0.445 
 M+ 3 7.9 3 4.3  
Pathological grading G1-2 17 54.8 35 57.4 0.816 
 G3 14 45.2 26 42.6  
Clinical staging I-III 8 21.1 21 29.6 0.337 
 IV 30 78.9 50 70.4  
Alcohol no/former 5 13.2 14 19.7 0.390 
 current 33 86.8 57 80.3  
Tobacco no/former 5 13.2 22 31.0 0.040 
 current 33 86.8 49 69.0  
HPV non-related1 31 81.6 50 74.6 0.415 
 related2 7 18.4 17 25.4  
Therapy adjuvant RT & RCT 22 57.9 49 69.0 0.246 
 definitive RT & RCT 16 42.1 22 31.0  
 all RT 28 73.7 44 62.0 0.218 
 all RCT 10 26.3 27 38.0  
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4.2 Co-expression of OPRPN and SMR3A in HNSCC cell lines 
and response to fractionated irradiation 
Experimental data of our research group demonstrated that SMR3A is expressed in 
HNSCC cell lines at low levels, but the relative amount of SMR3A-positive cells 
increase after fractionated irradiation (Grunow et al., 2017). To investigate whether 
OPRPN is co-expressed with SMR3A in HNSCC cell lines, a co-immunofluorescence 
staining (co-IF) was performed in FaDu and Cal27 cells. Similar to SMR3A, basal 
OPRPN protein expression was low and detected only in a sub-fraction of both cell 
lines (Figure 4-2B). However, upon fractionated IR prominent OPRPN expression was 
found in the majority of cells and was co-expressed with SMR3A (Figure 4-2B) 
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Figure 4-2: Co-expression of OPRPN and SMR3A in HNSCC cell lines in response 
to fractionated irradiation. 
(A) Schematic representation of the treatment protocol for fractionated irradiation (4x2Gy); (B) 
Representative pictures of the co-immunofluorescence staining confirms induced OPRPN (red 
signal) and SMR3A (green signal) expression upon fractionated irradiation. Cell nuclei were 
stained by Hoechst33324 (blue staining), white bar= 20μm.      
 
4.3 Expression of OPRPN in primary OPSCC and correlation 
with clinic-pathological features 
To determine whether aberrant OPRPN expression is relevant for the pathogenesis 
and/or the malignant progression of OPSCC, tissue microarrays with tissue samples of 
normal mucosa and OPSCC were stained by immunohistochemistry. A weak staining of 
OPRPN was observed in basal and supra-basal keratinocytes of normal mucosa, which 
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was utilized as reference (Figure 4-3A, B). A heterogeneous staining pattern of OPRPN 
protein was observed in primary OPSCC varying from low to high expression (Figure 
4-3C-F).  
 
Figure 4-3: OPRPN protein expression in normal mucosa and primary 
tumors of OPSCC patients. 
Representative pictures for OPRPN expression (signal in brown) in normal mucosa (A and B) 
and primary OPSCC with low (C and D) or high OPRPN protein levels (E and F) as determined 
by IHC staining of TMAs. Counterstaining of cell nuclei was performed with haematoxylin (signal 
in blue) to demonstrate tissue architecture. Scale bars equal 100 µm. 
 
Relative number of positive tumor cells and staining intensity were estimated by three 
observers independently. Both scores revealed a significant correlation (Spearman 
correlation of 0.825 and a Pearson correlation of 0.846) and were multiplied to obtain a 
final OPRPN expression score for further analysis. According to the final score, patients 
were arranged into two categories: patients with low protein expression of OPRPN 
(OPRPNlow) and those with high protein expression of OPRPN (OPRPNhigh). Overall, 
39.3% (55/140) of all patients were arranged as OPRPNlow and 60.7% (85/140) of those 
as OPRPNhigh.  
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Subsequently, OPRPN expression pattern and clinic-pathological features were 
compared, including age, gender, TNM status (AJCC Cancer Staging Manual 7th ed), 
pathological grade, HPV status, smoking and alcohol consumption. However, these 
parameters were not significantly correlated with OPRPN protein levels (Table 4-2). 
These data are in line with previous findings that SMR3A has no correlation with 
clinic-pathological features in OPSCC (Koffler et al., 2013). Accordingly, the regulation 
of opiorphin gene family is independent of initial events during neoplastic 
transformation and malignant progression of OPSCC.   
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Table 4-2: Correlation analysis for OPRPN expression and clinic-pathological 
features in the OPSCC patients Cohort 
Clinic-pathologica
l features 
 
OPRPNlow OPRPNhigh p-value 
Age(years) < 58 31 38 
0.178 
 ≥58 24 47 
Gender Male 39 63 
0.677 
 Female 16 22 
Tumor size T1/T2 25 36 
0.763 
 T3/T4 30 48 
 missing1  1  
Lymph node N0 11 15 
0.751 
 N+ 44 69 
 missing1  1  
Metastasis M0 49 80 
0.4312 
 M+ 4 3 
 missing1 2 2  
Clinical stage     I/II/III 17 25 
0.885 
 IV 38 59 
 missing1  1  
Pathological 
Grading 
G1/G2 29 38 
0.457 
 G3 19 33 
 missing1 7 14  
Tobacco Never/former 12 23 
0.484 
 Current 43 62 
Alcohol Never/former 11 16 
0.863 
 Current 44 69 
HPV status HPV-3 42 70 
0.387 
 HPV+4 13 15 
1 missing data, no information available; 2 Fisher’s exact test; 3viral DNA+RNA- or 
DNA-; 4viral DNA+RNA+ according to (Holzinger et al., 2012)  
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4.4 Correlation of OPRPN and SMR3A expression with 
disease-specific and progression-free survival 
Next, the prognostic value of OPRPN expression for disease-specific survival (DSS) 
and progression-free survival (PFS) of OPSCC patients was analyzed by Kaplan-Meier 
blots and log rank testing, but no statistically significant difference was observed 
(Figure 4-4). As final immunoreactivity scores of OPRPN and SMR3A had a moderate 
but significant correlation (Spearman correlation of 0.380 and a Pearson correlation of 
0.385) and a strong staining pattern of SMR3A was correlated significantly with a higher 
OPRPN immunoreactivity score (P<0.05), a combinatorial subgroup analysis was 
performed. However, patients with a SMR3AhighOPRPNhigh staining pattern in the tumor 
had a similar clinical outcome as compare to other subgroups (Figure 4-5).  
 
 
Figure 4-4: Progression-free survival and disease-specific survival in the cohort 
of OPSCC patients depending on OPRPN expression 
OPSCC patients were arranged into two categories: patients with low protein expression of 
OPRPN (OPRPNlow, final score<9; blue curves) and those with high protein expression of 
OPRPN (SMR3AhighOPRPNhigh, final score ≥ 9; green curves). Progression-free survival (A) and 
disease-specific survival (B) were evaluated by Kaplan-Meyer analysis and log-rank test. Total 
number of patients at risk were listed at indicated time points. 
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Figure 4-5: Combinatorial analysis of progression-free survival and 
disease-specific survival in the cohort of OPSCC patients depending on OPRPN 
and SMR3A expression 
(A). Boxplot depicts the OPRPN immunoreactivity score as mean value and 5%-95% for 
individual tumors with low, moderate or high SMR3A staining pattern. OPSCC patients were 
arranged into two categories: patients with high protein expression of OPRPN and SMR3A 
(OPRPNhighSMR3Ahigh; green curves) and those all other combinations (others, blue curves). 
Progression-free survival (B) and disease-specific survival (C) were evaluated by Kaplan-Meyer 
analysis and log-rank test. Total number of patients at risk were listed at indicated time points. 
 
Next, a combinatorial analysis has been performed in subgroup of OPSCC patients, 
which were treated with either definitive or post-surgical radiotherapy with or without 
chemotherapy. Concerning PFS and DSS, SMR3AhighOPRPNhigh staining pattern tumor 
revealed an unfavorable clinical outcome as compare to other subgroups (Figure 4-6). 
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Figure 4-6: Combinatorial analysis of progression-free survival and 
disease-specific survival in the subgroup of OPSCC patients with radiotherapy 
depending on OPRPN and SMR3A expression 
OPSCC patients with radiotherapy were arranged into two categories: patients with high protein 
expression of OPRPN and SMR3A (OPRPNhighSMR3Ahigh; green curves) and those all other 
combinations (others, blue curves). Progression-free survival (A) and disease-specific survival 
(B) were evaluated by Kaplan-Meyer analysis and log-rank test. Total number of patients at risk 
were listed at indicated time points. 
4.5 Inhibition of ESR2 signaling sensitizes HNSCC cell lines to 
irradiation 
Previous findings demonstrated that neither androgen receptor (AR) nor estrogen 
receptor 1 (ESR1) expression are expressed in FaDu or Cal27 cell lines under normal 
growth conditions. In contrast, estrogen receptor 2 (ESR2) was detected in both cell 
lines and was strongly up-regulated upon fractionated IR, suggesting a causal role in 
the response to irradiation (Grunow et al., 2017). To investigate whether inhibition of 
ESR2 alters the sensitivity of HNSCC cell lines upon radiotherapy, FaDu and Cal27 
cells were treated for 24h or 48h with 10nM fulvestrant, which is a selective ESR 
degrader (Lai and Crews, 2017). ESR2 protein levels were determined by 
immunofluorescence staining. Fulvestrant treatment revealed reduced ESR2 protein 
levels in FaDu but not Cal27 cells as compared to DMSO-treated controls (Figure 
4-7A).  
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In addition, no impact of fulvestrant on the relative survival fraction of FaDu cells and a 
slight increase of the relative survival fraction of Cal27 cells after fulvestrant treatment 
was found. Fulvestrant treatment significantly reduced the relative survival fraction of 
FaDu cells in combination with fractionated IR, suggesting a causal role of ESR2 in 
radioresistance (Figure 4-7B). However, no significant difference was observed for 
Cal27 cells. To further confirm the impact of ESR2 in radioresistance, both cell lines 
were treated with 4-Hydroxytamoxifen (4-OH-TAM), which resulted in a reduced relative 
survival fraction with or without fractionated IR in FaDu and Cal27 cell lines (Figure 4-7 
C). 4-OH-TAM belongs to a family of drugs, which are konwn as selective estrogen 
receptor modulators (SERMS) and function as either antagonists or agonists 
depending on the target tissue. In line with the less efficient reduction of ESR2 by 
fulvestrant, Cal27 cells exhibited a significant decrease in the relative survival fraction 
only with treatment of 4-OH-TAM but not fulvestrant (Figure 4-7 B, C).      
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Figure 4-7: Impact of fulvestrant or TAM treatment on FaDu and Cal27 with 
fractionated IR.  
(A) Representative pictures of immunofluorescence staining for ESR2 protein levels of control 
(DMSO) and 10 nM fulvestrant-treated FaDu and Cal27 cells. Graphs represent the relative 
survival fraction of FaDu and Cal27 cells after fractionated IR (4 x 2Gy) and either 30 nM 
fulvestrant (B) or 1 μM TAM (C) administration, respectively. Control groups are set to one and 
bars represent mean values ± standard error of the mean (SEM) of at least three independent 
experiments. *p≤0.05, ***p≤0.0005. (B and C were published in (Grunow et al., 2017)) 
 
4.6 Regulation of ESR2 and pERK1/2 in FaDu cells upon 
fractionated-IR and MEK1/2 inhibitor treatment 
An increasing body of experimental evidence supports that irradiation-induced 
phosphorylation of ERK1/2 (pERK1/2) serves as a mechanism of radioresistance in 
HNSCC (Affolter et al., 2016; Drigotas et al., 2013; Gupta et al., 2001). To investigate 
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the impact of the clinically tested MEK1/2 inhibitor PD-0325901(PD-901) on ERK1/2 
phosphorylation and ESR2 protein levels in HNSCC cell lines, FaDu cells were treated 
with 0.1μM PD-901 with or without fractionated-IR (4x2Gy) (Figure 4-8 A). Increase in 
pERK and ESR2 after fractionated IR was determined by IF staining (Figure 4-8 B) and 
confirmed for pERK by western blot analysis (Figure 4-8 C). As expected, inhibition of 
basal and IR-induced pERK levels was observed after PD-901 treatment. Elevated 
ESR2 levels after PD-901 treatment were found without IR but not with IR. In addition, 
neither basal nor IR-induce pERK levels were affected by fulvestrant treatment. 
Although both pERK and ESR2 are induced upon fractionated IR and seem to play 
significant roles in radioresistance, these data do no support a direct functional 
cross-talk between ERK signaling and regulation of ERS2 in irradiated FaDu cells. 
       
 
Figure 4-8: Effect of fractionated-IR and MEK1/2 inhibitor treatment on ESR2 and 
phospho-ERK1/2 protein levels in FaDu cells.  
(A) Schematic summary treatment protocol with the 0.1 μM PD-0325901 (PD) or 10nM 
Fulvestrant and fractionated IR (4 x 2Gy). ESR2 and pERK1/2 protein levels in FaDu cells after 
treatment was determined by immunofluorescence staining (B; red signal for pERK and green 
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signal for ESR2) and Western blot analysis with whole cell lysate (C). Cell nuclei were 
counterstained with Hoechst H33342 (blue signal). Scale bars = 20μm. 
 
4.7 Impact of MEK1/2 inhibitor on the radiosensitivity of FaDu 
and Cal27 cells 
Previous data demonstrated that fractionated-IR stimulated pERK as a potential 
mechanism of increased radioresistance. The elevation of pERK was almost 
completely restrained after treatment of FaDu cell with a MEK1/2 inhibitor. To 
investigate whether MEK inhibitor treatment alters the radiosensitivity of FaDu and 
Cal27, CFAs were performed using FaDu and Cal27 cells after treatment with 0.1 μM, 
0.3μM PD-901 with or without fractionated-IR (4x2Gy). In the absence of fractionated 
IR, a concentration dependent reduction in the survival fraction for both cell lines was 
observed. Moreover, FaDu cells were more sensitive to PD-901 treatment than Cal27 
cells. Administration of PD-901 sensitized FaDu and Cal27 cells to fractionated IR in a 
concentration dependent manner (Figure 4-9).      
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Figure 4-9: PD-901 treatment sensitizes HNSCC cell lines to fractionated IR.  
(A) Representative staining of control (DMSO) or PD-901 treated FaDu and Cal27 cells with or 
without fractionated IR (4x 2 Gy). (B) Graphs indicate the relative survival fraction of FaDu and 
Cal27 cells after treatment with given concentrations of PD-901 with or without fractionated IR (4 
x 2Gy). DMSO-treated control cells are normalized to one and bars depict mean values + SEM 
of three independent experiments. *P≤0.05, ** P≤0.005, ***P≤0.0005. 
 
4.8 Sensitivity of HNSCC cell lines to MEK1/2 inhibitor treatment 
To address whether PD-901 has a similar impact on survival and expansion of other 
HNSCC cell lines, CFAs using 0.1μM and 1μM PD-901 were performed in Detroit562, 
SCC4, SCC9 and SCC25. These experiments confirmed a concentration dependent 
reduction in the survival fraction for all cell lines, which was significant at a dose of 1Μm 
PD-901. However, it is worth noting that at lower PD-901 concentration (0.1μM) no 
significant difference was found for Cal27 and Detroit562 cells, indicating a higher level 
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of resistance. (Figure 4-10 A, B).             
 
Figure 4-10: Sensitivity of HNSCC cell lines to the treatment with the MEK1/2 
inhibitor PD-901.  
(A) Representative staining of a CFA with control (DMSO) or PD-901 treated HNSCC cell lines. 
(B) Graphs represent the relative survival fraction of HNSCC cell lines after treatment with 
indicated concentrations of PD-901. DMSO-treated control cells are normalized to one and bars 
depict mean values + SEM of three independent experiments. *P≤0.05, ** P≤0.005. 
 
4.9 Regulation of ESR2 in FaDu and Cal27 cells after cetuximab 
treatment 
The epidermal growth factor receptor (EGFR)-targeted IgG1 monoclonal antibody, 
cetuximab, has revealed clinical benefits in the therapy of HNSCC. Cetuximab 
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represents FDA-approved and European Medicines Agency-approved targeted therapy 
in HNSCC and is employed with no correlation with EGFR status (Bourhis et al., 2010). 
To monitor the impact of cetuximab on ESR2 expression in HNSCC cell lines, FaDu 
and Cal27 cells were treated with either 5 or 10 μg/ml cetuximab respectively, as a 
single dose (Figure 4-11A) or three times every second day (Figure 4-12A). ESR2 
protein levels were determined by Western blot analysis or IF staining. While a single 
dose treatment had no major impact on ESR2 protein levels in both cell lines as 
compared to controls (Figure 4-11B), a dose-dependent increase of ESR2 was 
detected in FaDu but not in Cal27 cells after repeated treatment with cetuximab. (Figure 
4-12B, C).         
 
 
Figure 4-11: Regulation of ESR2 by cetuximab in single dose treatment.  
(A) Schematic summary of the single dose cetuximab treatment protocol. (B) Expression of 
ESR2 in FaDu and Cal27 cells after cetuximab single dose treatment was demonstrated by 
Western blot analysis with whole cell lysate. Detection of β-actin served as a control for quantity 
and quality of protein lysates. 
 
 
 
 59 
 
 
Figure 4-12: Regulation of ESR2 by cetuximab in three times-repeated treatment.  
(A) Schematic summary of the repeated cetuximab treatment protocol. (B) Expression of ESR2 
in FaDu and Cal27 cells after repeated cetuximab treatment was demonstrated by Western blot 
analysis with whole cell lysates. (C) Signals were quantified by image J and bars in the graph 
show the ratio of ESR2 and β-actin. Data represent mean±SEM of two independent 
experiments measured in triplicates, *P≤0.05,**P≤0.005. (D) Representative pictures of an 
immunofluorescence staining for ESR2 (red signal) in FaDu and Cal27 cells after treatment with 
indicated concentrations of Cetuximab. Cell nuclei were counterstained with Hoechst H33342 
(blue signal). Scale bars = 20μm.  
 
4.10 Sensitivity of HNSCC cell lines to cetuximab 
Multiple clinical studies have confirmed a survival advantage for patients with locally 
advanced HNSCC, who were treated with Cetuximab in combination with radiotherapy 
as compared with irradiation alone considering PFS and DSS (Brockstein, 2011). 
Nevertheless, the response and sensitivity of individual patient to cetuximab varies 
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significantly. To address whether cetuximab has similar impact on HNSCC cell lines, 
CFAs were performed to evaluate the susceptibilities of several HNSCC cell lines to 
cetuximab. Our data revealed that SCC25 is more sensitive to cetuximab as compared 
to all other cell lines tested (Figure 4-13 A, B).       
 
Figure 4-13: Sensitivity of HNSCC cell lines to cetuximab.  
(A) Representative staining of a CFA with control (DMEM) or cetuximab treated HNSCC cell 
lines. (B) Graphs represent the relative survival fraction of HNSCC cell lines after treatment with 
indicated concentrations of cetuximab. DMEM-treated control cells are normalized to one and 
bars represent mean values + SEM of three independent experiments. *P≤0.05. 
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4.11 Regulation of pERK1/2 and PD-L1 by cetuximab 
treatment. 
Programmed death-1(PD-1) is an immune checkpoint receptor expressed in tumor 
infiltrating lymphocytes (TIL), which restricts activated T lymphocytes function (Hamid 
and Carvajal, 2013). Its cognate ligand, programmed death ligand-1 (PD-L1) is 
expressed on tumor cells, including HNSCC (Chen and Han, 2015; Hammerman et al., 
2015). The MAPK/ERK pathway is one of the downstream signaling pathways 
stimulated by EGFR. To assess the impact of cetuximab on pERK1/2 and PD-L1 
protein levels of HNSCC cell lines in single (Figure 4-14 A) and repeated treatment 
(Figure 4-15 A), whole protein lysate of several HNSCC cell lines were analyzed by 
Western blot. Data showed various regulatory effects on pERK/PD-L1 by cetuximab 
treatment in different cell lines. As expected, single cetuximab treatment reduced pERK 
levels in Cal27, Detroit562, SCC4, SCC9, and SCC25 cells as compared to controls. 
Moreover, Detroit562 and SCC9 exhibited a concentration dependent reduction of 
pERK levels. It is worth noting that SCC25, which was most sensitive to cetuximab, had 
the most effective reduction of pERK expression. By contrast, FaDu cells showed 
elevated pERK levels in response to cetuximab. There was no significant alteration of 
PD-L1 expression in Cal27, Detroit562 and SCC25 after single dose of cetuximab 
treatment. In addition, no obvious correlation between basal pERK and PD-L1 levels 
was found, but PD-L1 levels were decreased in FaDu, SCC4 and SCC9 cells after 
cetuximab treatment (Figure 4-14 B). In summary, these data demonstrate a 
heterogeneous response of short-term cetuximab treatment on PD-L1 levels, which is 
independent of ERK phosphorylation. 
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Figure 4-14: Regulation of pERK1/2 and PD-L1 by cetuximab after a single dose 
treatment.  
(A) Schematic summary of the short-term cetuximab treatment protocol. (B) Expression of pERK, 
total-ERK and PD-L1 in HNSCC cell lines after short-term cetuximab treatment was 
demonstrated by Western blot analysis with whole cell lysates. Detection of β-actin served as a 
control for quantity and quality of protein lysates.  
 
In terms of repeated cetuximab treatment, a similar trend with minor differences in ERK 
phosphorylation was observed for FaDu and SCC9. In contrast to short-term treatment, 
repeated cetuximab treatment of Detroit562 revealed elevated of pERK levels. There 
was no prominent alteration of pERK in Cal27, SCC4 and SCC25 after repeated 
cetuximab treatment, which all showed a reduced pERK levels after short-term 
treatment. Collectively, these data demonstrated that most HNSCC cell lines adapt to 
prolonged cetuximab treatment by means of ERK phosphorylation. In contrast, similar 
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trends for cetuximab dependent regulation of PD-L1 expression were found for FaDu, 
SCC4 and SCC9 cells, in part even more pronounced after repeated treatment. 
Down-regulation was observed in Detroit562 cells only after prolonged cetuximab 
treatment. It is worth noting that an elevated expression of PD-L1 was only detected for 
Cal27 after prolonged cetuximab treatment. Consistent with data after short-term 
treatment, a low expression of PD-L1 was found in SCC25 cells, which was not altered 
by cetuximab treatment (Figure 4-15B). Thus, data from repeated treatment 
experiments confirmed a heterogenous response on PD-L1 expression, which is 
independent of ERK phosphorylation. 
 
Together, these data indicate that the majority of HNSCC cell lines adapt to prolonged 
cetuximab treatment and regain baseline pERK levels. Moreover, up-regulation of 
PD-L1 was observed in Cal27 cells after long-term treatment, which is the most 
resistant cell line to cetuximab. These results provide a first proof-of-concept that 
up-regulation of PD-L1 might be a potential mechanism of resistance to cetuximab 
treatment in HNSCC. 
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Figure 4-15: Regulation of P-ERK1/2 and PD-L1 by cetuximab in three 
times-repeated treatment.  
(A) Schematic summary of the cetuxi long-term treatment protocol. (B) Expression of pERK, 
total-ERK and PD-L1 in HNSCC cell lines after long-term cetuximab treatment was 
demonstrated by Western blot analysis with whole cell lysates. Detection of β-actin served as a 
control for quantity and quality of protein lysates. 
 
4.12 Impact of MEK1/2 inhibitor treatment and fractionated IR 
on PD-L1 expression in FaDu cells 
Previous results demonstrated that administration of the MEK1/2 inhibitor PD-901 
sensitized FaDu and Cal27 cells to fractionated IR. To address the question, whether 
PD-901 and fractionated-IR have any impact on PD-L1 expression, whole protein lysate 
of FaDu cells after 0.1μM PD-901 treatment with or without fractionated IR (4x2Gy) 
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were analyzed by Western blot. Both PD-901 treatment and fractionated IR revealed an 
up-regulation of PD-L1 in FaDu cells. However, it is worth noting that induction of PD-L1 
protein levels was higher upon PD-901 treatment as compared to fractionated IR, and 
combined treatment did not further induce PDL1 expression (Figure 4-16).  
 
Figure 4-16: Impact of MEK1/2 inhibitor and fractionated IR on PD-L1 expression 
in FaDu cells.  
(A) PD-L1 and pERK1/2 expression in whole cell lysates of FaDu cells after 0.1μM PD-901 
treatment, fractionated-IR (4 x 2Gy) or combined treatment was determined by Western blot 
analysis. Detection of pERK1/2 protein levels served as a control for MEK1/2 inhibitor efficacy 
and detection of β-Actin served as a control for quantity and quality of protein lysates. (B, C) 
Signals were quantified by image J and bars in graphs show the ratio of the target proteins and 
β-actin. Data represent mean±SEM of two independent experiments measured in triplicates, 
*P≤0.05,**P≤0.005.  
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4.13 Regulation of p-ERK1/2 and PD-L1 by MEK1/2 inhibitor 
treatment. 
As no remarkable induction of PD-L1 by fractionated IR was detected in FaDu cells, 
further experiments were conducted with PD-901 without fractionated IR. To determine 
whether a similar trend of PD-L1 regulation is evident in other HNSCC cell lines, the 
effect of PD-901 on p-ERK1/2 and PD-L1 were assessed by Western blot analysis. 
Again, after single treatment, pERK1/2 levels were suppressed at a dose of 0.1 and 
1μM PD-901 in all cell lines (Figure 4-17 A). Notably, only SCC25 cells showed a 
dose-dependent response to PD-901 concerning ERK1/2 phosphorylation. However, 
PD-L1 expression was not altered by PD-901 treatment in the majority of cell lines, only 
SCC4 cells exhibited a down-regulation of PD-L1 in response to short-term PD-901 
treatment (Figure 4-17 B).  
 
In terms of repeated treatment (Figure 4-18 A), a potent inhibition of ERK 
phosphorylation was observed in all HNSCC cell lines after treatment with 0.1μM of 
PD-901. Consistent with the short-term treatment data, PD-L1 expression was not 
altered by PD-901 in Detroit562, SCC9 and SCC25, but elevated PD-L1 expression 
was found in FaDu cells. Moreover, SCC4 cells displayed a reduced expression of 
PD-L1 but a lower extent of variation as compared to findings of short-term treatment. A 
down-regulated expression of PD-L1 as compared to controls was also detected for 
Cal27 cells (Figure 4-18 B). 
 
Taken together, these data confirmed that PD-L1 regulation in HNSCC cell lines is 
largely independent of MEK-ERK signaling. Only in SCC4 cells, loss of ERK 
phosphorylation by the MEK1/2 inhibitor is accompanied by reduced PD-L1 protein 
levels. 
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Figure 4-17: Regulation of P-ERK1/2 and PD-L1 by PD-901 in single dose 
treatment.  
(A) Schematic summary of the short-term PD-901 treatment protocol. (B) Expression of pERK, 
total-ERK and PD-L1 in HNSCC cell lines after short-term PD-901 treatment was demonstrated 
by Western blot analysis with whole cell lysates. Detection of β-actin served as a control for 
quantity and quality of protein lysates. 
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Figure 4-18: Regulation of P-ERK1/2 and PD-L1 by PD-901 in three times-repeated 
treatment.  
(A) Schematic summary of the long-term PD-901 treatment protocol. (B) Expression of pERK, 
total-ERK and PD-L1 in HNSCC cell lines after long-term treatment 0.1μM PD-901 was 
demonstrated by Western blot analysis with whole cell lysates. Detection of β-actin served as a 
control for quantity and quality of protein lysates. 
 
4.14 Effects of MEK1/2 inhibitor on Akt and Histone H2AX 
phosphorylation in HNSCC cell lines 
Recent findings have established PI3K (Phosphoinositide 3-kinase) and MEK signaling 
cascades as drivers of carcinogenesis and potential target for 
pharmacological intervention in a wide range of human cancers, including HNSCC 
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(Cancer Genome Atlas, 2015). However, treatment with MEK inhibitors often result in 
elevated AKT phosphorylation, reducing the efficacy of MEK inhibitors as single agents 
(Faber et al., 2009; Hoeflich et al., 2009; Yoon et al., 2009). To investigate whether the 
MEK1/2 inhibitor PD-901 affects PI3K signaling in HNSCC cell lines, AKT 
phosphorylation (p-AKT) was determined in whole cell lysate of HNSCC cell lines after 
repeated treatment with 0.1μM PD-901. As shown in (Figure 4-19), AKT 
phosphorylation was not affected by PD-901 in all cell lines tested. Next, the effects of 
PD-901 on DNA damage marker, phosphorylation of Histone H2A.X were also 
investigated. In most HNSCC cell lines, PD-901 treatment did not alter levels of pH2A.X 
except for SCC25 cells, which showed a marked up-regulation of pH2A.X expression. 
 
 
Figure 4-19: Effects of MEK1/2 inhibitor on AKT and Histone H2AX 
phosphorylation in HNSCC cell lines.  
AKT and Histone H2AX phosphorylation of in HNSCC cell lines after long-term treatment with 
0.1μM PD-901 was determined by Western blot analysis. Detection of β-Actin served as a 
control for quantity and quality of protein lysates. 
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4.15 MEK1/2 inhibitor induced cellular senescence in HNSCC 
cell lines 
Cellular senescence is a process in which cultured cells stop dividing and undergo a 
form of irreversible growth arrest. An increasing body of studies have established a 
crucial role of cellular senescence in cancer prevention (Nardella et al., 2011). To 
address whether MEK1/2 inhibitor induce cellular senescence in HNSCC cell lines, 
cells were treated several times with PD-901 at a concentration of 1μM and assayed for 
β-galactosidase (β-gal) activity. Microscopic inspection revealed a flattened cellular 
morphology in most HNSCC cell line after PD-901 treatment, which is characteristic 
feature of senescent cells (Figure 4-20 A, B). In addition, prominent β-gal staining was 
detected in FaDu, Cal27, SCC4 and SCC9 cells. Interestingly, no increase in β-gal 
activity was observed in Detroit562 and SCC25 cells (Figure 4-20 C). Furthermore, 
Detroit562, which is a resistant cell line to MEK1/2 inhibitor, revealed no β-gal activity 
with or without PD-901 treatment. Thus, these data suggest that inhibition of MEK1/2 
activity induce senescence in sensitive but not in resistant HNSCC cell lines.         
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Figure 4-20: Long-term treatment of PD-901 induced cellular senescence in 
HNSCC cell lines.  
HNSCC cell lines were treated after long term with 1μM PD-901and stained for β-galactosidase. 
Blue cells were stained with senescence-associated β-galactosidase. Representative images 
(scale bar=100 μm) for FaDu, Cal27, SCC9 and SCC25 shown in (A), for Detroit562 and SCC4 
shown in (B), with quantitation analysis in (C).  
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5. Discussion 
5.1 Opiorphins serve as a surrogate marker for radioresistance. 
The therapeutic strategy of loco-regionally advanced HNSCC has developed gradually 
from surgery to radiotherapy (Gregoire et al., 2015). Approximately 75% of patients with 
HNSCC will benefit from radiotherapy as part of a primary therapeutic scheme or as 
adjuvant therapy after surgery (Barton et al., 2014). Although significant improvements 
have been achieved in novel techniques and new protocols of radiotherapy for the 
treatment of HNSCC, intrinsic and acquired radioresistance remain crucial barriers for 
curative therapy of HNSCC. Unraveling molecular mechanism of radioresistance and 
identifying new biomarkers for HNSCC patients at high risk for treatment failure is 
urgently needed. 
 
Previous data identified the mouse homolog of human SMR3A gene, Smr1, to be 
differentially expressed in primary and recurrent tumors of an orthotopic mouse 
xenograft model for oral cancer (Acuna Sanhueza et al., 2012). In addition, elevated 
SMR3A protein expression has been detected in 36% of patients with OPSCC and 
serves as a prognostic risk factor for unfavorable PFS and OS (Koffler et al., 2013). It is 
worth noting that an increased transcript levels of Muc10, which is the mouse homolog 
of the human OPRPN gene, another member of the opiorphin gene family, was found in 
recurrent tumors after surgery as compared to matched primary tumors. It indicates a 
general principle of regulation and function of opiorphin family members in the 
progression of tumor recurrence and treatment failure (Acuna Sanhueza et al., 2012). 
So far, the opiorphin family members have been studied in a variety of physiological 
and pathological conditions, such as erectile dysfunction (ED), colonic motility and 
nociception, pain and mood disorders, hypoxic response, etc. (Fu et al., 2014; Javelot 
et al., 2010; Tian et al., 2009; Tong et al., 2008).  
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Studies on erectile physiology revealed a crucial role for SMR3A and OPRPN in ED 
suggesting that all members of the opiorphin family can act as markers for organic ED 
in human patients. These findings provided compelling evidence that opiorphins are 
key players in male sexual function and their downstream pathways might represent 
novel pharmacological targets (Davies et al., 2007; Messaoudi et al., 2004; Tong et al., 
2008; Tong et al., 2007). It was also reported that the pentapeptide opiorphin reveals 
potent analgesic function in chemical and mechanical pain models as an inhibitor of 
pain perception. In addition, the pain-suppressive efficacy is equal to morphine in the 
behavioral rat model, suggesting opiorphin might act as a potential initiator to develop 
novel candidate drug for pain control (Wisner et al., 2006). Opiorphin has been 
identified as a potent inhibitor of two enkephalin-degrading enzymes, namely neutral 
endopeptidase (NEP; also known as CD10) and aminopeptidase N (NEP; also known 
as CD13). Many previous studies demonstrated that CD10 and CD13 function as 
ectoenzymes to inactivate neuropeptides and regulate signaling pathways involving in 
tumor progression and invasion (Carl-McGrath et al., 2006; Fujita et al., 2007; 
Kawamura et al., 2007; Kuniyasu et al., 2010; Luo et al., 2009; Sorensen et al., 2013). 
Moreover, a positive regulation of opiorphin family members by hormone signaling have 
been reported in several studies (Chua et al., 2009; Senorale-Pose et al., 1998).  
 
Likewise, our findings suggested that ESR2 signaling regulates SMR3A expression and 
plays an important role in resistance to radiotherapy. Furthermore, the results in a new 
cell culture model of fractionated irradiation provided compelling experimental evidence 
for the existence and expansion of a subpopulation of radioresistant tumor cells, which 
were characterized by ESR2, SMR3A and OPRPN expression. Notwithstanding, a 
statistically significant correlation was not observed between OPRPN expression 
pattern and clinical outcome of patients with OPSCC. Combined expression of ESR2 
and OPRPN or SMR3A was associated with unfavorable clinical prognosis post 
definitive or adjuvant radiotherapy, suggesting that opiorphin-related genes serve as a 
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surrogate marker for HNSCC cells with intrinsic radioresistance.      
 
5.2 Distinct functions of ESR subtypes in cancer 
Estrogen exerts its functions in target tissues mainly via two members of the nuclear 
receptor superfamily: ESR1 (also known as ERα) and ESR2 (also known as ERβ) 
(Heldring et al., 2007). Both receptors possess four functional domains, harboring a 
DNA-binding domain (DBD), a ligand-binding domain (LBD) and two transcriptional 
activation functions (AF-1 and AF-2). These domains share a proportional homology 
between ESR1 and ESR2 (Figure 5-1) (Roman-Blas et al., 2009). Both receptors 
mediate their effects as transcription factors in the nucleus when they are bound to their 
specific ligands (Osborne et al., 2001). They can also interact and modulate the activity 
of each other, and participate in membrane and cytoplasmic signaling cascades 
(Bjornstrom and Sjoberg, 2005). In the present study, a prominent ESR2 but not ESR1 
expression was found in HNSCC cell lines and tumor tissues. An active ESR2 signaling 
as a common event in HNSCC predicts treatment resistance and has a prognostic 
value for patient survival. However, we did not observe significant difference between 
ESR2 staining pattern and gender, in line with the findings that ESR expression and 
function in HNSCC cell lines is independent of the gender of patients from whom the 
cell lines were derived (Egloff et al., 2009). These data suggest that ESR2 likely plays a 
significant role in HNSCC of both males and females. The synthesis of estrogen 
through the action of aromatase in extra gonadal has been identified as the major 
source of estrogen for men and post-menopausal women. Aromatase has been shown 
to be expressed in various tumors and play a significant role in the growth of 
malignancies, including HNSCC (Cheng et al., 2006). It is worth noting that larger tumor 
size and tobacco consumption is significantly correlation with negative ESR2 staining, 
which is consistent with our survival data that OPSCC without detectable ESR2 reveal 
a poor prognosis. These results also suggest that ESR2 displays dual roles in tumor 
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growth and radioresistance. Loss of ESR2 could contribute to growth of tumor cells 
during neoplastic transformation and malignant development, while ESR2-positive 
tumor cells reveal radioresistance and survive after radiotherapy.     
 
Figure 5-1. Structural composition of ESR1 and ESR2  
(modified from (Roman-Blas et al., 2009)).  
 
Studies of the proportion of ESR-positive HNSCC vary considerably. Either ESR 
subtype has been detected in only 2.7% of HNSCC tumors by ESR assay and in 50.7% 
of HNSCC tumors by immunohistochemistry (Lukits et al., 2007; Schuller et al., 1984). 
Several reports show that HNSCC tumors and cell lines display no expression of ESR1 
or the proportion was less than 10% of HNSCC tumors or cell lines (Ferguson et al., 
1987; Hagedorn and Nerlich, 2002). A study indicated that ESR expression was 
observed more frequently in laryngeal tumor than other head and neck tumors. 
However, another study reported that both ESR1 and ESR2 were detected in the 
majority of HNSCC tumors independent anatomical tumor sites (Egloff et al., 2009). In 
line with our findings, a study in oral squamous cell carcinoma reported high levels of 
ESR2 expression, but ESR1 expression was neither observed in primary tumor tissues 
nor several cultured cell lines, supporting a specific regulation and function of ESR2 in 
HNSCC (Ishida et al., 2007). The differences between our study and other reports 
could be due to the various antibodies and the distinct techniques, including 
immunohistochemistry (IHC) and ligand-binding assay. Currently, most laboratories 
determine the ESR status by IHC on formalin-fixed paraffin-embedded tissue 
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specimens (Harvey et al., 1999). Interestingly, it has been reported that ESR2 plays a 
role in smoking-related susceptibility of male and female patients with lung cancer 
(Kiyohara and Ohno, 2010). Risks related to tobacco are higher for women than men in 
HNSCC. ESR-mediated events are likely responsible for the higher smoking-related 
hazards for women than men owing to higher circulating levels of estrogen. However, 
amount of estrogen in men are sufficient to exert biological effects because aromatase 
expression can be detected in normal oral keratinocytes and oral SCC, which can 
catalyze the conversion of androgen to estrogen (Cheng et al., 2006). These findings 
indicate that ESR also plays a significant role in pathogenesis of male patients with 
HNSCC.         
 
So far, few studies have evaluated the contribution of ESR on the clinical outcome of 
HNSCC patients. In 2009, Egloff and coworkers investigated the expression levels of 
ESR1 and ESR2 in HNSCC by immunohistochemistry, revealing that patients with high 
ESR1 nuclear staining tend to have shorter progression-free survival as compared to 
patients with low levels (Egloff et al., 2009). The relationship between ESR levels and 
clinical outcome has been studied in more detail for other cancer entities. In breast 
cancer, ESR1 protein levels are associated with low tumor grade and negative lymph 
node metastasis. ESR1-positive tumor cells tend to be less invasive and reveal a better 
prognosis (Platet et al., 2004). The expression of ESR2 isotypes has been determined 
in 442 invasive breast cancers. This study revealed that ESR2, in particular the isotype 
ESR2-1 is associated with better survival in triple-negative breast cancers and sensitive 
to tamoxifen treatment. Moreover, nuclear accumulation of ESR2-2 was negatively 
associated with metastasis and vascular invasion. In contrast, a cytoplasmic ESR2-2 
expression pattern was correlated with more unfavorable prognosis and resistance to 
chemotherapy (Honma et al., 2008). In a study of non-small cell lung carcinoma 
(NSCLC), ESR1 overexpression was associated with shorter overall survival and was 
correlated with EGFR mutations, serving as an independent factor for unfavorable 
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prognosis (Stabile et al., 2011). An elevated nuclear ESR2 level correlated with better 
survival in men only (Schwartz et al., 2005; Skov et al., 2008), also predicting a 
favorable outcome for lung adenocarcinoma after EGFR tyrosine kinase inhibitor 
treatment (Nose et al., 2011). These data suggest that ESR subtypes and subcellular 
localization may act as important determinants of involvement in various tumors. 
Accordingly, it will be a major challenge for the future to assess the subcellular 
localizations of ESR2 in a larger cohort of HNSCC patients. 
 
5.3 Targeting the ESR signaling for cancer therapy 
To the best of our knowledge, there are no reports evaluating the inhibition of ESR 
signaling in combination with radiotherapy for HNSCC patients. Presented results 
revealed that two well-established anti-estrogen drugs, 4-Hydroxytamoxifen 
(4-OH-TAM) and fulvestrant (Figure 5-2), can sensitize HNSCC cell lines to fractionated 
irradiation in a colony-forming assay (CFA). These findings suggest that combination of 
anti-estrogen drugs and irradiation has a synergic effect on restraint proliferation in 
HNSCC cells, which might reveal implications for combination therapy in 
subpopulations of HNSCC patients.  
 
Anti-estrogen therapy exerts effects by competing with estrogens for binding to the ESR, 
most widely used for the management of ESR-related breast cancer. In 1971, a new 
anti-estrogen tamoxifen was reported firstly in treatment for patients with breast cancer 
(Cole et al., 1971). Until now tamoxifen is the most frequently prescribed anti-estrogen, 
revealing a significant clinical benefit for breast patients. Tamoxifen is a 
triphenylethylene and several derivatives have been produced, including toremifene 
(chloro-tamoxifen), 3-hydroxytamoxifen (droloxifene) and 4-hydroxytamoxifen 
(4-OH-TAM). 4-OH-TAM, which was used in this study, is a potent metabolite of TAM. 
This anti-estrogen drug reveals the equal pharmacologic activity as TAM, but 
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possesses a higher binding affinity for ESRs (Jordan et al., 1977). The anti-estrogen 
TAM is an effective cytostatic drug which is employed in combination of fractionated IR 
for the therapy of ESR positive breast cancer (Anonymous, 1988; Anonymous, 1992; 
Stewart, 1992). Wazer and colleagues (Wazer et al., 1989) observed that 
growth-inhibitory doses of TAM reduce the radiosensitivity of MCF-7 breast cancer cells 
in vitro. Furthermore, an assay in vivo assessed the efficacy of treatment by irradiation 
and concurrent tamoxifen, indicating that combined irradiation and tamoxifen display 
significant suppression in tumor volumes and tumor growth (Kantorowitz et al., 1993). It 
has been clarified that the tumor-suppression effect of tamoxifen on breast carcinoma 
cells is owing to the expression of cyclin-dependent kinase inhibitors, particularly 
P21WAF1/CIP, which is regulated by wild type P53 (Ichikawa et al., 2008). Another report 
demonstrated that anti-estrogen might alter radiosensitivity independent of the ESR 
status, suggesting that hormone therapy function through estrogen receptors but also 
independent mechanisms (Paulsen et al., 1996). 
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Figure 5-2. Structure of 4-hydroxtamoxifen (A) and fulvestrant (B). 
 
Fulvestrant, one of the more promising new anti-estrogen drugs, is the first new type of 
ESR antagonists that down-regulates ESR function as a ‘pure’ antagonist with no 
partial agonist properties as have been described for tamoxifen (Wakeling et al., 1991). 
Fulvestrant competitively prevents binding of estradiol to ESRs. The binding of 
Fulvestrant and ESR prevents receptor dimerisation and energy-dependent nuclear 
shuttling (Dauvois et al., 1993; Fawell et al., 1990). ESR protein degradation is 
aggravated due to the unstable fulvestrant-ESR complex. Therefore, fulvestrant binds 
and accelerates degradation of ESR proteins, resulting in a block of estrogen signaling 
via ESR degradation (Figure 5-3) (Osborne et al., 1995; Osborne et al., 2004; Wakeling, 
2000; Wardley, 2002). This pure antagonist has been approved for treatment of 
hormone receptor positive metastatic breast cancer or locally advanced inoperable 
tumors in postmenopausal women (Lee et al., 2017). Our results revealed that 
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fulvestrant can eliminate the ESR2 expression in FaDu cells but to a lesser extend in 
Cal27 cells, which might explain a more prominent increased radiosensitivity in FaDu 
cells. Furthermore, fulvestrant alone has no negative impact on colony growth of both 
cell lines, even a slight increase in Cal27 cells. It might be due to a higher sensitivity of 
Cal27 to irradiation, resulting in unimproved radiosensitivity by fulvestrant. In breast 
cancer, a study reported that fulvestrant can sensitize ESR-positive tumor cells to 
radiotherapy (Wang et al., 2013). In view of these data and our results, endocrine 
therapy can enhance radiosensitivity by inhibition of tumor cell proliferation and growth, 
paving the way for future clinical trials in which administration of anti-estrogen therapy 
in combination with radiotherapy will be assessed for HNSCC patients.    
 
Figure 5-3. Mechanism of the steroidal ERα antagonist, fulvestrant, at the level of 
transcriptional regulation. 
(ERE= estrogen response element; F= fulvestrant). Figure was modified from (Ratanaphan, 
2012). 
5.4 Interaction of ESR with EGFR signaling 
Activities of the ESR2 could be explained by genomic or non-genomic signaling 
pathways. Non-genomic signaling pathways depend on second messengers such as 
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cyclic adenosine monophosphate (cAMP) and calcium, or the activation of PI3K and 
MAPK (Siegfried et al., 2009). In lung cancer, the steroid receptor coactivator (SRC) 
protein and the osteopontin (OPN) contribute to the cross-talk between the ESR and 
the EGFR (Figure 5-4) (Hsu et al., 2017). Hence, ESRs share common intracellular 
non-genomic signaling pathways with EGFR, suggesting that activation of ESR 
signaling might induce resistance to EGFR-targeted therapy (Hsu et al., 2017). A crucial 
role of tyrosine kinase receptors of the EGFR/HER family has been well established in 
growth and invasion HNSCC cells. Moreover, a functional crosstalk between ESR and 
EGFR signaling has been reported for HNSCC, in which estrogen and EGF stimulate 
MAPK signaling. In addition, the combination of fulvestrant and gefitinib, an EGFR 
tyrosine kinase inhibitor, maximally inhibits cell invasion (Egloff et al., 2009). A 
concentration-dependent induction of ESR2 was detected in FaDu cells after long-term 
treatment with cetuximab. Blocking ERK signaling, one of downstream pathways 
following EGFR activation, might activate ERS2 signaling in FaDu cell under normal 
growth condition. Taken together, these data provide experimental evidence that ESR2 
interacts with the EGFR signaling pathway as alternate signaling mechanisms.  
 
It is worth noting that dual targeting of ESR and EGFR signaling has already been 
proposed for the treatment of lung cancer. The combined treatment inhibited cell 
proliferation and suppressed tumor growth more effectively than individual treatment in 
vitro and in vivo (Marquez-Garban et al., 2007; Osborne et al., 2005; Siegfried et al., 
2012; Stabile et al., 2005). Furthermore, in NSCLC cell lines, the EGFR protein level 
was reduced in response to estrogen and induced in response to fulvestrant. 
Conversely, the ESR2 expression was down-regulated in response to EGF and 
up-regulated in response to gefitinib, suggesting an inverse regulation of ESR and 
EGFR signaling. (Stabile et al., 2005). Nose et al (Nose et al., 2009) demonstrated a 
strong association between nuclear expression of ESR2 and EGFR mutations in lung 
adenocarcinoma, indicating that the favorable prognosis of nuclear ESR2 expression is 
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influenced by EGFR mutations. These studies have supported a rationale for combined 
targeting of ESR and EGFR pathways. A pilot clinical study of combined therapy with an 
EGFR inhibitor and fulvestrant in NSCLC revealed enhanced anti-tumor effects 
(Traynor et al., 2009). Several phase II clinical trials are currently in progress to 
evaluate hormone therapy effects on advanced NSCLC, and in combination with an 
EGFR tyrosine kinase inhibitor (ClinicalTrials.gov).   
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Figure 5-4. Schematic model for mechanisms on how the estrogen receptor (ESR) 
interacts with the epidermal growth factor receptor (EGFR) to influence the 
cellular signaling even and cells growth in the lung cancer.  
Estrogen activates the steroid receptor coactivator (SRC) protein, which in turn, triggers the 
EGFR signaling pathway. Furthermore, estrogen increases the osteopontin (OPN) level and 
facilitates the lung carcinoma cell migration via the MEK/ERK signaling pathway. Whereupon, 
the SRC and OPN contribute to the cross-talk between the ESR and the EGFR.  
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5.5 Effects of EGFR-MAPK pathway on PD-L1 expression in 
HNSCC 
A growing body of more specific drugs targeting key regulators of oncogenic signaling 
cascades or immune checkpoints have been or will be approved in the near future for 
the treatment of HNSCC patients in combination with radiotherapy. Hence, further 
insights into the anti-tumor effects of targeted therapies along with radiotherapy are 
urgently needed. To address this issue several cell culture models were established to 
investigate the impact of drugs targeting the EGFR-MEK-MAPK pathway (e.g. 
Cetuximab and MEK1/2 inhibitor) on tumor cell survival and clonal expansion as well as 
expression of the immune checkpoint inhibitor PD-L1. It is well known that tumors have 
developed distinct mechanisms to alleviate T-cells antitumor responses and escape the 
immune elimination, including stimulation of inhibitory immune checkpoint receptors 
(Sharma and Allison, 2015). Current immune-based therapies of HNSCC are focused 
on targeting T-cell inhibitory receptors, like antagonists of the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA4) or programmed cell death protein 
(PD1)-PD1 ligand 1 (PD-L1) pathways, known as immune checkpoint inhibitors (Ferris, 
2015; Whiteside, 2017). PD-L1 is the main ligand of PD1, which counteracts T-cell 
induced immune response and signaling. PD-L1 can be expressed on the surface of 
many solid tumor cells including HNSCC (Lee et al., 2016). Sofia Lyford-Pike et al 
(Lyford-Pike et al., 2013) have provided evidence that the PD-1/PD-L1 pathway offers 
an immune-privileged site for HPV infection and serves as an adaptive resistance 
mechanism of tumors against host. Moreover, PD-L1 expression has been identified as 
a significant biomarker for patients with HPV-negative HNSCC at high risk of treatment 
failure, which appears to be related to Axl/PI3 kinase signaling (Skinner et al., 2017). 
Multiple factors have been demonstrated to affect PD-L1 expression including 
epithelial-mesenchymal transition (EMT), viruses, and sub-lethal damage induced by 
cytotoxic chemotherapy via MAPK or JAK-STAT pathway signaling (Atefi et al., 2014; 
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Jiang et al., 2013; Ritprajak and Azuma, 2015; Yang et al., 2013).    
 
In the present study, the impact of single or repeated treatment with cetuximab on 
ERK1/2 phosphorylation and PD-L1 protein levels was investigated in HNSCC cell lines. 
The data indicate a heterogeneous and context-specific response of cetuximab on 
PD-L1 expression after short or long-term treatment, which was independent of ERK 
phosphorylation. The majority of HNSCC cell lines under long-term treatment exhibited 
regain of ERK phosphorylation as compared to the short-term treatment. Up-regulation 
of PD-L1 was observed in Cal27 cells with long-term treatment, which was the most 
resistant cell line to cetuximab treatment. These results provide a proof-of-concept that 
up-regulation of ERK phosphorylation and PD-L1 expression might be a potential 
mechanism of resistance to cetuximab treatment in HNSCC, suggesting potential 
benefits of combining cetuximab with immunotherapy. In line with the presented results, 
PD-L1 expression is believed to be associated with EMT features, immune escape and 
treatment resistance, predicting an unfavorable clinical outcome (Kakavand et al., 2017; 
Ock et al., 2016; Yan et al., 2016)  
 
Cetuximab therapy has been reported to impact expression of checkpoint receptors on 
circulating and tumor-infiltrating lymphocytes (TILs). Cetuximab-activated natural killer 
(NK) cells selectively excluded intratumoral regulatory T cells (Treg) and maintained 
effector T cells (Jie et al., 2015). Targeting PD-1/PD-L1 axis may stimulate cytolytic 
function of NK cells, cetuximab induced antibody dependent cellular cytotoxicity 
(ADCC), suggesting combined treatment of Durvalumab, an anti-PD-L1 monoclonal 
antibody, with cetuximab might provide enhanced benefit for HNSCC patients (Bonomo 
et al., 2017). Furthermore, an elevation of PD-L1 positive peripheral blood T-cells after 
EGFR inhibitor treatment has been significantly associated with the clinical prognosis in 
NSCLC, providing the implication that up-regulation of PD-L1 might be one of the 
mechanisms of acquired resistance to EGFR inhibitors (Meniawy et al., 2016).  
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The effects of a specific drug targeting ERK signaling, one of the EGFR downstream 
pathways, on radioresistance were further address in HNSCC cell lines. Up-regulation 
of ERK phosphorylation was observed in FaDu cells after fractionated IR, which is in 
line with a previous study (Affolter et al., 2016). PD-0325901 (PD-901) is a 
second-generation small molecular inhibitor that restraints the activation of ERK by 
inhibition of MEK1/2. Presented CFA data have revealed that PD-901 improves the 
radiosensitivity of HNSCC cell lines, providing potential clinical benefit from 
combination treatment of MEK1/2 inhibitor and radiotherapy. Up-regulation of PD-L1 
protein expression was observed in FaDu cells after treatment with PD-901 with or 
without fractionated IR. It is worth noting that induction of PD-L1 protein level was 
higher upon PD-901 treatment as compared to fractionated IR, and combined treatment 
did not further induce PD-L1 expression in FaDu cells. To gain further insight into the 
impact of MEK inhibitor on ERK1/2 phosphorylation and PD-L1 expression in HNSCC 
cell lines, their levels were examined after single or repeated administration by western 
blot analysis. The presented data confirmed that PD-L1 regulation in HNSCC cell lines 
in vitro is mainly independent of MEK-ERK signaling.  
 
The effect of targeted therapy on expression and signaling of immune checkpoint 
inhibitor and the potential combination treatment with immune-based drugs have been 
reported in several studies (Brauner et al., 2016; Comin-Anduix et al., 2010; Wilmott et 
al., 2012). In line with our findings, PD-L1 expression was analyzed in a larger panel of 
melanoma cell lines with or without treatment of MAPK inhibitors, showing no 
straight-forward cell-intrinsic regulation of PD-L1 expression by MAPK signaling (Atefi 
et al., 2014). However, PD-L1 expression was found to be regulated by MAPK signaling 
in a study of lymphomas (Yamamoto et al., 2009). In a murine carcinoma model, 
trametinib, a MEK inhibitor, synergized in combination with targeting PD1, PD-L1, and 
CTLA-4 antibody to increase antitumor efficacy (Liu et al., 2015). The inconsistency in 
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the discovery of these studies with our findings may attribute to the diversity in signaling 
context of HNSCC and other tumors. Interestingly, another recent study demonstrates 
that inhibition of the HER2/EGFR signaling pathway reduced PD-L1 expression and 
cytokines release in HER2-amplified cancer cells. Moreover, the PI3K but not MEK 
pathway was involved in reduction of PD-L1 expression in these cell lines, indicating 
that the regulation of PD-L1 expression by the EGFR/HER2 pathway may be 
dependent on the PI3K-AKT-mTOR signaling pathway (Koung Jin Suh, 2017).  
5.6 Conclusion and perspective 
In summary, obtained results from a new cell culture model of fractionated irradiation 
provided compelling experimental evidence for the existence and expansion of a 
subpopulation of radioresistant tumor cells, which were characterized by ESR2 and 
opiorphin gene (SMR3A, OPRPN) expression. Notwithstanding, a statistically 
significant correlation was not observed between OPRPN expression pattern and 
clinical outcome of patients with OPSCC. Combined expression of ESR2 and OPRPN 
or SMR3A was associated with unfavorable clinical prognosis post definitive or adjuvant 
radiotherapy, suggesting that opiorphin-related genes serve as a surrogate marker for 
HNSCC cells with intrinsic radioresistance. Moreover, treatment with 
4-hydroxytamoxifen or Fulvestrant, two well-established antagonists of estrogen 
receptor signaling, increases the sensitivity of HNSCC cell lines upon fractionated 
irradiation in vitro, paving the way for future clinical trials in which administration of 
anti-estrogen therapy in combination with radiotherapy will be assessed for HNSCC 
patients.     
 
In addition, several cell culture models have been established to investigate the impact 
of drugs targeting the EGFR-MEK-MAPK pathway (Cetuximab and MEK1/2 inhibitor) 
on tumor cell survival and clonal expansion as well as expression of ESR2 and PD-L1. 
A concentration-dependent induction of ESR2 was detected in FaDu cells after 
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long-term treatment with cetuximab. Blocking ERK signaling, one of the downstream 
pathways of EGFR activation, can activate ERS2 signaling in FaDu cell under normal 
growth condition. These data provide experimental evidence that ESR2 interacts with 
the EGFR signaling pathway as alternate signaling mechanisms. The presented data 
indicated that impact of cetuximab on PD-L1 after short or long-term inhibition is 
heterogeneous but independent of ERK phosphorylation. The majority of HNSCC cell 
lines with long-term treatment regain phosphorylation of ERK1/2 as compared to 
short-term treatment, and up-regulation of PD-L1 was observed in the most resistant 
cell line with long-term treatment. These novel results provide a proof-of-concept that 
up-regulation of ERK phosphorylation and PD-L1 levels might be a potential 
mechanism of resistance to cetuximab treatment in HNSCC, suggesting potential 
benefits of combining cetuximab with immunotherapies. Furthermore, the experimental 
data not only reveal that PD-901, a MEK1/2 inhibitor, increases radiosensitivity of 
HNSCC cell lines, providing potential clinical benefit from combination treatment of 
MEK inhibitor and radiotherapy but also confirmed that PD-L1 regulation in HNSCC cell 
lines is mainly independent of MEK-ERK signaling. Taken together, these novel findings 
suggest a complex and context-dependent regulation of ESR2 as well as PD-L1 upon 
inhibition of the EGFR-MEK-MAPK signaling cascade, and might provide potential 
molecular targets for HNSCC treatment in the future.  
 
Several issues should be addressed in future studies: 1). generation and analysis of 
HNSCC cell clones with a stable silencing of ESR2 expression using shRNA or 
CRISPR/Cas9 technology. With this cell culture models, ESR-dependent signaling and 
gene regulatory networks could be identified by global gene expression analysis. 2). 
expression and regulation of ESR2 in mouse tumor models, including HNSCC patient 
derived xenografts in vivo. 3). Functional characterization of other signaling pathways 
(e.g. PI3K, JAK-STAT, NFkB) involved in cell-intrinsic and extrinsic pathways of 
targeted-EGFR or PD-L1 regulation in vitro and in vivo. 
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6. Summary 
Head and neck squamous cell carcinoma (HNSCC) is one of most common human 
malignancies worldwide with high tumor-related morbidity and mortality. Unraveling 
molecular mechanism of treatment resistance and identifying new biomarkers for 
HNSCC patients at high risk for treatment failure is urgently needed. Previous data 
have provided an experimental evidence that a subpopulation of radiotherapy resistant 
tumor cells reveals co-expression of estrogen receptor 2 (ESR2) and submaxillary 
gland androgen regulated protein 3A (SMR3A) after fractionated irradiation (IR). In first 
part of the present study, ESR2 expression was assessed by immunohistochemistry 
(IHC) staining on tissue microarrays (TMAs) containing tumor specimens of OPSCC 
patients, which were treated with either definitive or post-surgical radiotherapy with or 
without adjuvant chemotherapy. Statistical analysis revealed that a subgroup of patients 
with positive ESR-2 and high SMR3A had an unfavorable clinical outcome as compared 
to those with low SMR3A expression. Furthermore, a new cell culture model of 
fractionated irradiation provided compelling experimental evidence for the existence 
and expansion of a subpopulation of radioresistant tumor cells, which were 
characterized by ESR2, opiorphin genes (SMR3A, OPRPN) expression. Nevertheless, 
the protein expression of OPRPN, another member of the opiorphin gene family, and 
clinical outcome of patients with OPSCC were not significantly correlated. Combined 
expression of ESR2 and OPRPN or SMR3A was associated with an unfavorable 
clinical prognosis post definitive or adjuvant radiotherapy, suggesting that 
opiorphin-related genes serve as surrogate markers for HNSCC cells with intrinsic 
radioresistance. Treatment with 4-hydroxytamoxifen or fulvestrant, two well-established 
antagonists of estrogen receptor signaling, increased the sensitivity of HNSCC cell 
lines upon fractionated irradiation in vitro. These data provide a strong evidence in 
which evaluation of ESR2 and opiorphin gene co-expression in primary tumor samples 
supports the identification of HNSCC patients with a higher risk for treatment failure 
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after radiotherapy, who might benefit from an adjuvant treatment with antagonists of 
estrogen receptor signaling.  
 
In this study, several cell culture models have been established to address the impact of 
drugs targeting the EGFR-MEK-MAPK pathway (cetuximab and MEK1/2 inhibitor) on 
tumor cell survival and clonal expansion as well as expression of ESR2 and 
programmed death-ligand 1 (PD-L1). A concentration-dependent induction of ESR2 
was detected in FaDu cells after long-term treatment with cetuximab. Blocking ERK 
signaling, one of the downstream pathways of EGFR activation, can activate ERS2 
signaling in FaDu cell under normal growth condition. These data provide the evidence 
that ESR2 interacts with the EGFR signaling pathway as alternate signaling 
mechanisms. The impact of cetuximab on PD-L1 after short or long-term inhibition has 
been clarified, which tends to be heterogenous but independent of ERK 
phosphorylation. The majority of HNSCC cell lines with long-term treatment regain 
expression of ERK phosphorylation as compared to short-term, and up-regulation of 
PD-L1 was observed in the most resistant cell line with long-term treatment. These 
results provide a proof-of-concept that up-regulation of PD-L1 might be a potential 
mechanism of resistance to cetuximab treatment in HNSCC, suggesting potential 
benefits of combining cetuximab with immunotherapy. Moreover, the experimental data 
not only reveal that PD-901, a MEK1/2 inhibitor, increases the radiosensitivity of 
HNSCC cell lines, providing potential clinical benefit from combination treatment of 
MEK1/2 inhibitor and radiotherapy but also confirmed that PD-L1 regulation in HNSCC 
cell lines is mainly independent of MEK-ERK signaling. Taken together, these novel 
findings suggest a complex and context-dependent regulation of ESR2 as well as 
PD-L1 upon inhibition of the EGFR-MEK-MAPK signaling cascade, may provide 
potential molecular targets for HNSCC treatment in the future.  
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8. Supplements 
Supplement 8-1. Univariate Cox regression models for progression-free and 
disease-specific survival 
 Progression-free survival Disease-specific survival 
Risk factor HR 95% CI p-value HR 95% CI p-value 
Gender 
female vs male1 
1.111 0.626-1.973 0.719 1.139 0.627-2.069 0.668 
Age [years] 
≥58 vs <581 
0.647 0.403-1.039 0.072 0.715 0.433-1.180 0.189 
T status 
T3-4 vs T1-21 
1.831 1.097-3.055 0.021 2.189 1.238-3.871 0.007 
N status 
N+ vs N01 
0.981 0.486-1.980 0.957 1.090 0.518-2.296 0.820 
Pathological grading 
G3 vs G1-21 
1.074 0.627-1.840 0.795 0.985 0.551-1.762 0.961 
Clinical staging 
IV vs I-III1 
1.394 0.814-2.387 0.226 1.842 0.998-3.401 0.051 
Alcohol 
current vs 
never/former1 
1.073 0.563-2.043 0.831 1.187 0.603-2.337 0.620 
Tobacco 
current vs 
never/former1 
2.868 1.466-5.617 0.002 2.606 1.284-5.290 0.008 
HPV status2 
related vs non-related1 
0.264 0.120-0.577 0.001 0.282 0.121-0.655 0.003 
Subgroup 
ESR2posSMR3Ahigh vs 
ESR2posSMR3Alow,1 
2.514 1.333-4.739 0.004 2.442 1.260-4.730 0.008 
Subgroup 
All others vs 
ESR2posSMR3Alow,1 
2.492 1.469-4.230 0.001 2.307 1.319-4.036 0.003 
HR = Hazard ratio, CI = confidence interval, 1reference group, 2related = viral 
DNA+RNA+, non-related = viral DNA+RNA- or viral DNA- according to Holzinger et al., 
2012. 
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Supplement 8-2. Multivariable Cox regression models for progression-free and 
disease-specific survival (N=66) 
 Progression-free survival Disease-specific survival 
Risk factor HR 95% CI p-value HR 95% CI p-value 
Gender 
female vs male1 
1.109 0.506-2.427 0.796 1.042 0.476-2.280 0.919 
Age [years] 
≥58 vs <581 
0.618 0.295-1.296 0.209 0.624 0.280-1.394 0.250 
Clinical staging 
IV vs. I-III1 
1.530 0.745-3.142 0.247 1.966 0.909-4.251 0.086 
Alcohol 
current vs 
never/former1 
1.166 0.493-2.760 0.726 1.490 0.612-3.631 0.380 
Tobacco 
current vs 
never/former1 
2.016 0.720-5.646 0.182 1.799 0.639-5.011 0.268 
HPV status2 
related vs non-related1 
0.429 0.130-1.480 0.184 0.415 0.124-1.388 0.153 
Therapy 
RCT vs RT1 
0.700 0.308-1.591 0.395 0.713 0.295-1.725 0.453 
Subgroup 
ESR2posSMR3Ahigh vs 
ESR2posSMR3Alow,1 
1.965 0.960-4.025 0.065 1.988 0.912-4.333 0.084 
N=66 cases were included based on complete clinical data, HR = Hazard ratio, CI = 
confidence interval, 1reference group, 2related = viral DNA+RNA+, non-related = viral 
DNA+RNA- or viral DNA- according to Holzinger et al., 2012. 
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Supplement 8-3. Multivariable Cox regression models for progression-free and 
disease-specific survival (N=103) 
 Progression-free survival Disease-specific survival 
Risk factor HR 95% CI p-value HR 95% CI p-value 
Gender 
female vs male1 
1.004 0.554-1.822 0.999 0.959 0.519-1.770 0.893 
Age [years] 
≥58 vs <581 
0.686 0.421-1.118 0.130 0.719 0.426-1.213 0.216 
Clinical staging 
IV vs. I-III1 
1.544 0.876-2.721 0.133 2.039 1.081-3.843 0.028 
Alcohol 
current vs 
never/former1 
1.077 0.516-1.965 0.983 1.237 0.623-2.455 0.544 
Tobacco 
current vs 
never/former1 
1.855 0.922-3.734 0.083 1.783 0.854-3.722 0.124 
HPV status2 
related vs non-related1 
0.298 0.134-0.659 0.003 0.308 0.130-0.727 0.007 
Therapy 
RCT vs RT1 
0.928 0.543-1.584 0.783 0.943 0.532-1.675 0.842 
Subgroup 
All others vs 
ESR2posSMR3Alow,1 
1.877 1.075-3.277 0.027 1.561 0.872-2.796 0.134 
N=103 cases were included based on complete clinical data, HR = Hazard ratio, CI = 
confidence interval, 1reference group, 2related = viral DNA+RNA+, non-related = viral 
DNA+RNA- or viral DNA- according to Holzinger et al., 2012.  
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